Hemos leído sobre ... Miopatías inflamatorias
-
Volkov J, Nunez D, Mozaffar T, Stadanlick J, Werner M, Vorndran Z, et al.
Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I/II trial.
Mol Ther. 2024 Sep 7:S1525-0016(24)00591-4. doi: 10.1016/j.ymthe.2024.09.009. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/39245937/ -
Vignesh P, Nadig PL, Basu S, Reddy S, Tyagi R, Dod A, et al.
Profile of patients with Juvenile Dermatomyositis and Anti-MDA5 autoantibodies.
Pediatr Res. 2024 Sep 23. doi: 10.1038/s41390-024-03551-3. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/39313554/ -
Veldkamp SR, van Wijk F, van Royen-Kerkhof A, Ha Jansen M
Personalised medicine in juvenile dermatomyositis: From novel insights in disease mechanisms to changes in clinical practice
Best Pract Res Clin Rheumatol. 2024 Sep;38(3):101976. doi: 10.1016/j.berh.2024.101976.
https://pubmed.ncbi.nlm.nih.gov/39174374/ -
Schonenberg-Meinema D, Cutolo M, Smith V.
Capillaroscopy in the daily clinic of the pediatric rheumatologist.
Best Pract Res Clin Rheumatol. 2024 Sep;38(3):101978. doi: 10.1016/j.berh.2024.101978.
https://pubmed.ncbi.nlm.nih.gov/39034217/ -
Thumbe A, Kumar A, Ajibade A, Sapkota H, Sheeran TP, Venkatachalam S, et al.
Management of bone health in idiopathic inflammatory myopathies: A two-center audit in the United Kingdom and Hong Kong.
Int J Rheum Dis. 2024 Sep;27(9):e15268. doi: 10.1111/1756-185X.15268.
https://pubmed.ncbi.nlm.nih.gov/39297554/
-
Wallwork RS, Paik JJ, Kim H.
Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons.
Expert Opin Pharmacother. 2024 Aug;25(12):1625-1645. doi: 10.1080/14656566.2024.2392021.
https://pubmed.ncbi.nlm.nih.gov/39136388/ -
Liu L, Hou Y, Zhao D.
Clinicopathological features and treatment outcome of juvenile idiopathic inflammatory myopathies with anti-melanoma differentiation associated gene 5 antibodies: A case series study.
Medicine (Baltimore). 2024 Aug 30;103(35):e39523. doi: 10.1097/MD.0000000000039523.
https://pubmed.ncbi.nlm.nih.gov/39213243/ -
Tsuji H, Nakashima R, Yasumi T, Sasai T, Ichimura Y, Shirakashi M, et al.
Differences in the autoantibody phenotypes and long-term outcomes between juvenile- and adult-idiopathic inflammatory myopathies.
Semin Arthritis Rheum. 2024 Aug 8;68:152530. doi: 10.1016/j.semarthrit.2024.152530.
https://pubmed.ncbi.nlm.nih.gov/39142036/ -
Valões CCM, Arabi TM, Braga ALF, Campos LMA, Aikawa NE, Kozu KT, et al.
The influence of environmental factors related to Juvenile Dermatomyositis (JDM), its course and refractoriness to treatment.
Adv Rheumatol. 2024 Aug 30;64(1):64. doi: 10.1186/s42358-024-00408-5.
https://pubmed.ncbi.nlm.nih.gov/39215374/ -
Veldkamp SR, van Wijk F, van Royen-Kerkhof A, Jansen MH.
Personalised medicine in juvenile dermatomyositis: From novel insights in disease mechanisms to changes in clinical practice.
Best Pract Res Clin Rheumatol. 2024 Aug 22:101976. doi: 10.1016/j.berh.2024.101976.
https://pubmed.ncbi.nlm.nih.gov/39174374/ -
Joseph AJ, Dhakal B, Erla SR, Singh Y, Singh L, Upadhyay AD, et al.
Prevalence and Clinical Implications of Autoantibodies in Juvenile Dermatomyositis: A Single-Center Experience From India.
J Clin Rheumatol. 2024 Aug 22. doi: 10.1097/RHU.0000000000002127.
https://pubmed.ncbi.nlm.nih.gov/39167787/
-
Carriquí-Arenas S, Mosquera JM, Quesada-Masachs E, López M, Clemente D, Boteanu A, Udaondo C, de Inocencio J, Nieto JC, Riancho L, Núñez E, Sánchez-Manubens J, Lirola MJ, Roldán R, Camacho M, Martínez M, Medrano M, Alcañiz P, Antón J, Iglesias E.
Clinical characteristics and prognostic factor in juvenile dermatomyositis: data of the Spanish registry.
Pediatr Rheumatol Online J. 2024 Jul 22;22(1):66. doi: 10.1186/s12969-024-00999-9.
https://pubmed.ncbi.nlm.nih.gov/39039532/
-
Sener S, Cam V, Ozen S, Batu ED.
Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature.
Semin Arthritis Rheum. 2024 Jun;66:152426. doi: 10.1016/j.semarthrit.2024.152426.
https://pubmed.ncbi.nlm.nih.gov/38442462/ -
Kim H.
Updates on efficacy and safety janus kinase inhibitors in juvenile dermatomyositis.
Expert Rev Clin Immunol. 2024 Jun;20(6):589-602. doi: 10.1080/1744666X.2024.2312819.
https://pubmed.ncbi.nlm.nih.gov/38299575/ -
Rodríguez-Lozano AL, Mata-Aguilera X, Rivas-Larrauri F, Bustamante-Ogando JC, Gutierrez-Hernandez A, Bojalil-Cabildo A, Scheffler-Mendoza S, Yamazaki-Nakashimada M.
Subcutaneous immunoglobulin for the treatment of calcinosis associated with juvenile dermatomyositis.
Int J Rheum Dis. 2024 Jun;27(6):e15239. doi: 10.1111/1756-185X.15239.
https://pubmed.ncbi.nlm.nih.gov/38923294/
-
Ioan A, Farkas OM, Cochino AV.
Factors Associated With Complete Clinical Response and Remission in a Cohort of Romanian Children With Juvenile Dermatomyositis.
J Clin Rheumatol. 2024 May 16. doi: 10.1097/RHU.0000000000002092.
https://pubmed.ncbi.nlm.nih.gov/38753166/ -
Manwatkar A, Naresh K, Mathew J, Nair AV, Goel R, Yadav B, et al.
Comparison of rituximab efficacy in treatment-naive and refractory inflammatory myopathies: experiences from a tertiary care centre.
Rheumatology (Oxford). 2024 May 30:keae307. doi: 10.1093/rheumatology/keae307. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/38814804/
-
Nguyen HD, Jouen F, Déchelotte B, Cordel N, Gitiaux C, Bodemer C, et al.; UK JDM Cohort and Biomarker study.
TIF1-gamma IgG2 isotype is not associated with malignancy in juvenile dermatomyositis patients
Rheumatology (Oxford). 2024 Mar 18:keae182. doi: 10.1093/rheumatology/keae182. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/38498839/ -
Ciaglia K, Ghawji M, Caraballo M, Sloan E.
Successful Treatment of Rapidly Progressive Interstitial Lung Disease in Juvenile Dermatomyositis
Pediatrics. 2024 Mar 1;153(3):e2023063268. doi: 10.1542/peds.2023-063268.
https://pubmed.ncbi.nlm.nih.gov/38361479/ -
Zhang L, Zhang H, Liu S, Zhang N, Wang Y.
A less common case of anti-MDA5 and anti-Ro52 antibody-positive juvenile dermatomyositis complicated with macrophage activation syndrome.
Clin Case Rep. 2024 Mar 20;12(3):e8613. doi: 10.1002/ccr3.8613.
https://pubmed.ncbi.nlm.nih.gov/38515992/ -
Yoshida A, Li Y, Maroufy V, Kuwana M, Sazliyana Shaharir S, Makol A, et al; COVAD Study Group.
Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey.
Rheumatol Adv Pract. 2024 Mar 4;8(2):rkae028. doi: 10.1093/rap/rkae028.
https://pubmed.ncbi.nlm.nih.gov/38524696/
-
Raupov R, Suspitsin E, Preobrazhenskaya EV, Kostik M.
Interferon type I signature associated with skin disease in juvenile dermatomyositis.
Front Med (Lausanne). 2024 Feb 14;11:1214920. doi: 10.3389/fmed.2024.1214920.
https://pubmed.ncbi.nlm.nih.gov/38420360/ -
Covert LT, Prinz JA, Swain-Lenz D, Dvergsten J, Truskey GA.
Genetic changes from type I interferons and JAK inhibitors: clues to drivers of juvenile dermatomyositis.
Rheumatology (Oxford). 2024 Feb 5:keae082. doi: 10.1093/rheumatology/keae082.
https://pubmed.ncbi.nlm.nih.gov/38317053/ -
Rosina S, Consolaro A, Pistorio A, Rebollo-Giménez A, Bracaglia C, Dolezalova P, Guilaisne Bernard-Medina A, Herlin T, Trachana M, Vargová V, Wouters C, Carenini L, Ruperto N, Ravelli A; Paediatric Rheumatology International Trials Organisation (PRINTO).
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index.
RMD Open. 2024 Feb 2;10(1):e003093. doi: 10.1136/rmdopen-2023-003093.
https://pubmed.ncbi.nlm.nih.gov/38307698/
-
Sherman MA, Noroozi Farhadi P, Pak K, Trieu EP, Sarkar K, Targoff IN, Neely ML, Mammen AL, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.
Myositis-associated autoantibodies in juvenile myositis are associated with refractory disease and mortality.
Arthritis Rheumatol. 2024 Jan 25. doi: 10.1002/art.42813. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/38272842/
-
Demortier J, Vautier M, Chosidow O, Gallay L, Bessis D, Berezne A, et al.
Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature.
Rheumatology (Oxford). 2023 Dec 1;62(12):3932-3939. doi: 10.1093/rheumatology/kead154.
https://pubmed.ncbi.nlm.nih.gov/37010495/ -
Sherman MA, Yang Q, Gutierrez-Alamillo L, Pak K, Flegel WA, Mammen AL, Rider LG, Casciola-Rosen LA; Childhood Myositis Heterogeneity Collaborative Study Group.
Clinical features and immunogenetic risk factors associated with additional autoantibodies in anti-transcriptional intermediary factor 1γ juvenile-onset dermatomyositis.
Arthritis Rheumatol. 2023 Dec 7. doi: 10.1002/art.42768. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/38059274/ -
Li D, Jia W, Zhou L, Hao Y, Wang K, Yang B, Yang J, Luo D, Fu Z.
Increased expression of the p-STAT3/IL-17 signaling pathway in patients with dermatomyositis.
Mod Rheumatol. 2023 Dec 22;34(1):129-136. doi: 10.1093/mr/roac147.
https://pubmed.ncbi.nlm.nih.gov/36478263/
-
Khojah A, Morgan G, Klein-Gitelman MS, Pachman LM.
Juvenile dermatomyositis: association between nail fold capillary end row loop- area under the curve- and disease damage indicators.
Pediatr Rheumatol Online J. 2023 Nov 13;21(1):137. doi: 10.1186/s12969-023-00919-3.
https://pubmed.ncbi.nlm.nih.gov/37957619/ -
Kassani PH, Ehwerhemuepha L, Martin-King C, Kassab R, Gibbs E, Morgan G, Pachman LM.
Artificial intelligence for nailfold capillaroscopy analyses - a proof of concept application in juvenile dermatomyositis.
Pediatr Res. 2023 Nov 22. doi: 10.1038/s41390-023-02894-7
https://pubmed.ncbi.nlm.nih.gov/37993641/ -
Shaw KS, Reusch DB, Castillo RL, Hashemi KB, Sundel R, Dedeoglu F, Vleugels RA.
Rapid Improvement in Recalcitrant Cutaneous Juvenile Dermatomyositis With Anifrolumab Treatment.
JAMA Dermatol. 2023 Nov 11. doi: 10.1001/jamadermatol.2023.4744.
https://pubmed.ncbi.nlm.nih.gov/37950917/ -
Helm M, Hollins C, Kessler W, Miller JJ, Foulke G. 14-Gauge
Coaxial Bone Needle Leads to Superior Results When Injecting Calcinosis Cutis.
J Drugs Dermatol. 2023 Nov 1;22(11):7180. doi: 10.36849/JDD.7180.
https://pubmed.ncbi.nlm.nih.gov/37943265/ -
Huang B, Huang W, Hao S.
Cutaneous ulceration in juvenile dermatomyositis with anti-melanoma differentiation-associated gene 5.
Pediatr Dermatol. 2023 Nov 7. doi: 10.1111/pde.15469.
https://pubmed.ncbi.nlm.nih.gov/37936561/ -
Fukushima K, Yoshida T, Yamazaki H, Takamatsu N, Nagai T, Osaki Y, Harada M, Nishino I, Okiyama N, Sugie K, Izumi Y.
A Case of Anti-NXP2 Antibody-positive Juvenile Dermatomyositis with Characteristic Fascial Thickening on Muscle Ultrasound and Improvement with Immunotherapy.
Intern Med. 2023 Nov 6. doi: 10.2169/internalmedicine.2720-23.
https://pubmed.ncbi.nlm.nih.gov/37926535/ -
Balan S, Madan S.
Idiopathic Inflammatory Myopathies.
Indian J Pediatr. 2023 Nov 3. doi: 10.1007/s12098-023-04896-z.
https://pubmed.ncbi.nlm.nih.gov/37919486/
-
Pachman LM, Morgan G, Klein-Gitelman MS, Ahsan N, Khojah A.
Nailfold capillary density in 140 untreated children with juvenile dermatomyositis: an indicator of disease activity.
Pediatr Rheumatol Online J. 2023 Oct 13;21(1):118. doi: 10.1186/s12969-023-00903-x.
https://pubmed.ncbi.nlm.nih.gov/37828536/
-
Strauss T, Günther C, Schnabel A, Wolf C, Hahn G, Lee-Kirsch MA, Brück N.
Rapid and sustained response to JAK inhibition in a child with severe MDA5 + juvenile dermatomyositis.
Pediatr Rheumatol Online J. 2023 Sep 19;21(1):104. doi: 10.1186/s12969-023-00894-9.
https://pubmed.ncbi.nlm.nih.gov/37726751/ -
Doskaliuk B, Ravichandran N, Sen P, Day J, Joshi M, Nune A, et al; COVAD study group; Chinoy H, Agarwal V, Aggarwal R, Gupta L.
Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study.
Rheumatol Int. 2023 Sep;43(9):1651-1664. doi: 10.1007/s00296-023-05345-y.
https://pubmed.ncbi.nlm.nih.gov/37351634/ -
Osman M, Martins KJB, Wong KO, Vu K, Guigue A, Cohen Tervaert JW, et al.
Incidence and prevalence, and medication use among adults living with dermatomyositis: an Alberta, Canada population-based cohort study.
Sci Rep. 2023 Sep 30;13(1):16444. doi: 10.1038/s41598-023-43880-7.
https://pubmed.ncbi.nlm.nih.gov/37777591/ -
Chang Y, Shan X, Ge Y.
Macrophage activation syndrome in juvenile dermatomyositis: a case report and a comprehensive review of the literature.
Pediatr Rheumatol Online J. 2023 Sep 21;21(1):106. doi: 10.1186/s12969-023-00893-w.
https://pubmed.ncbi.nlm.nih.gov/37735702/
-
Sener S, Cam V, Ozen S, Batu ED.
Biologic drugs in the treatment of juvenile dermatomyositis: a literature review.
Clin Rheumatol. 2023 Aug 16. doi: 10.1007/s10067-023-06740-3. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/37582998/ -
Khojah A, Morgan G, Klein-Gitelman MS, Pachman LM.
Juvenile Dermatomyositis: Association between Nail Fold Capillary End Row Loops Area Under the Curve and Disease Damage Indicators.
Res Sq [Preprint]. 2023 Aug 21:rs.3.rs-3235841. doi: 10.21203/rs.3.rs-3235841/v1.
https://pubmed.ncbi.nlm.nih.gov/37674726/ -
Perfetto J, Yoo DA, Tamashiro CY, Perron MM, Vasquez-Canizares N, Wahezi DM.
Impact of SARS-CoV-2 on the clinical presentation of juvenile idiopathic inflammatory myopathies.
Pediatr Rheumatol Online J. 2023 Aug 11;21(1):82. doi: 10.1186/s12969-023-00861-4.
https://pubmed.ncbi.nlm.nih.gov/37568191/ -
Zhang Y, Costin C.
Cyclophosphamide-induced liver injury during treatment of interstitial lung disease in juvenile dermatomyositis.
BMJ Case Rep. 2023 Aug 9;16(8):e252592. doi: 10.1136/bcr-2022-252592.
https://pubmed.ncbi.nlm.nih.gov/37558279/
-
Curiel RV, Nguyen W, Mamyrova G, Jones D, Ehrlich A, Brindle KA, Haji-Momenian S, Sheets R, Kim H, Jones OY, Rider LG; Abatacept in Dermatomyositis (AID) Trial Investigators.
Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy.
Arthritis Rheumatol. 2023 Jul;75(7):1229-1237. doi: 10.1002/art.42450.
https://pubmed.ncbi.nlm.nih.gov/36657109/ -
Yi BY, Marrs J, Acharya P, Sura A, Cidon M.
Risk factors for developing calcinosis in juvenile dermatomyositis: subcutaneous and myofascial edema in initial magnetic resonance imaging.
Rheumatol Int. 2023 Jul 11. doi: 10.1007/s00296-023-05385-4. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/37432516/ -
Mehta P, Lawrence A, Gupta L, Misra DP, Agarwal V, Misra R, Aggarwal A.
Long-standing and poorly controlled disease in juvenile dermatomyositis is associated with calcinosis: a real-world experience from a low-middle income country.
Rheumatol Int. 2023 Jul 5. doi: 10.1007/s00296-023-05377-4. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/37405442/ -
Gofshteyn JS, Mansfield L, Spitznagle J, Balasubramanian P, Cardenas J, Miller T et al.
Association of Juvenile Dermatomyositis Disease Activity With the Expansion of Blood Memory B and T Cell Subsets Lacking Follicular Markers.
Arthritis Rheumatol. 2023 Jul;75(7):1246-1261. doi: 10.1002/art.42446.
https://pubmed.ncbi.nlm.nih.gov/36648920/ -
Duvvuri B, Pachman LM, Hermanson P, Wang T, Moore R, Ding-Hwa Wang D et al.
Role of mitochondria in the myopathy of juvenile dermatomyositis and implications for skeletal muscle calcinosis.
J Autoimmun. 2023 Jul;138:103061. doi: 10.1016/j.jaut.2023.103061.
https://pubmed.ncbi.nlm.nih.gov/37244073/
-
Zhou W, Dong L, Liu X, Dong C, Zhang H.
Juvenile dermatomyositis and nephrotic syndrome: A case report and a mini literature review.
Front Pediatr. 2023 May 2;11:1149785. doi: 10.3389/fped.2023.1149785. PMID: 37205220; PMCID: PMC10185749.
https://pubmed.ncbi.nlm.nih.gov/37205220/ -
Karasawa R, Yudoh K, Sato T, Tanaka M, Sabbagh SE, Flegel WA, Mammen AL, Jarvis JN, Rider LG; Childhood Myositis Heterogeneity Study Group.
Association of Anti-TPM4 autoantibodies with vasculopathic cutaneous manifestations in juvenile dermatomyositis.
Rheumatology (Oxford). 2023 May 5:kead203. doi: 10.1093/rheumatology/kead203. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/37144941/ -
Gao FQ, Zhang JM, Li CF.
Paraneoplastic pemphigus misdiagnosed as juvenile dermatomyositis: A case report.
Int J Rheum Dis. 2023 May 11. doi: 10.1111/1756-185X.14684. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/37166030/
-
Chriswell ME, Fuhlbrigge RC, Lovell MA, Monson M, Bloom JL.
Why so low? An unusual case of myositis in a child.
Pediatr Rheumatol Online J. 2023 Apr 18;21(1):36. doi: 10.1186/s12969-023-00816-9.
https://pubmed.ncbi.nlm.nih.gov/37072782/ -
Sato H, Inoue Y, Kawashima Y, Konno R, Ohara O, Kuwana M, Kobayashi N, Takezaki S, Akioka S.
In-depth proteomic analysis of juvenile dermatomyositis serum reveals protein expression associated with muscle-specific autoantibodies.
Rheumatology (Oxford). 2023 Apr 13:kead165. doi: 10.1093/rheumatology/kead165. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/37052527/
-
Kim H, Saygin D, Douglas C, Wilkerson J, Erman B, Pistorio A, et al; International Myositis Assessment and Clinical Studies Group (IMACS) and Paediatric Rheumatology INternational Trials Organization (PRINTO).
Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles.
Rheumatology (Oxford). 2023 Mar 17:kead111. doi: 10.1093/rheumatology/kead111. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36929918/ -
Sherman MA, Pak K, Pinal-Fernandez I, Flegel WA, Targoff IN, Miller FW, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group.
Anti-Sp4 autoantibodies co-occur with anti-TIF1 and are associated with distinct clinical features and immunogenetic risk factors in juvenile myositis.
Arthritis Rheumatol. 2023 Mar 30. doi: 10.1002/art.42512. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36996276/ -
Pinotti CS, Cannon L, Dvergsten JA, Wu EY.
Calcinosis in juvenile dermatomyositis: Updates on pathogenesis and treatment.
Front Med (Lausanne). 2023 Mar 2;10:1155839. doi: 10.3389/fmed.2023.1155839.
https://pubmed.ncbi.nlm.nih.gov/36936211/ -
Ceribelli A, Tonutti A, Isailovic N, De Santis M, Selmi
Interstitial lung disease associated with inflammatory myositis: Autoantibodies, clinical phenotypes, and progressive fibrosis.
Front Med (Lausanne). 2023 Mar 16;10:1068402. doi: 10.3389/fmed.2023.1068402.
https://pubmed.ncbi.nlm.nih.gov/37007784/ -
Bandeira M, Dourado E, Melo AT, Martins P, Fraga V, Ferraro JL, et al.
Predictors of cardiac involvement in idiopathic inflammatory myopathies.
Front Immunol. 2023 Mar 8;14:1146817. doi: 10.3389/fimmu.2023.1146817.
https://pubmed.ncbi.nlm.nih.gov/36969246/ -
Qian J, Li R, Chen Z, Cao Z, Lu L, Fu Q.
Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients.
Front Immunol. 2023 Mar 17;14:1151695. doi: 10.3389/fimmu.2023.1151695.
https://pubmed.ncbi.nlm.nih.gov/37006269/
-
Gibbs E, Khojah A, Morgan G, Ehwerhemuepha L, Pachman LM.
The von Willebrand Factor Antigen Reflects the Juvenile Dermatomyositis Disease Activity Score.
Biomedicines. 2023 Feb 14;11(2):552. doi: 10.3390/biomedicines11020552.
https://pubmed.ncbi.nlm.nih.gov/36831088/ -
Kaplan MM, Çelikel E, Güngörer V, Ekici Tekin Z, Gürsu HA, Polat SE, Cinel G, Çelikel Acar B.
Cardiac involvement in a case of juvenile dermatomyositis with positive anti-melanoma differentiation associated protein 5 antibody.
Int J Rheum Dis. 2023 Feb 28. doi: 10.1111/1756-185X.14630. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36852875/ -
Zhou K, Cai R, Ma Y, Tan Q, Wang X, Li J, Shum HPH, Li FWB, Jin S, Liang X.A
Video-Based Augmented Reality System for Human-in-the-Loop Muscle Strength Assessment of Juvenile Dermatomyositis.
IEEE Trans Vis Comput Graph. 2023 Feb 22;PP. doi: 10.1109/TVCG.2023.3247092. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/37027743/ -
Marstein HS, Witczak BN, Godang K, Olarescu NC, Schwartz T, Flatø B, et al.
Adipokine profile in long-term juvenile dermatomyositis, and associations with adipose tissue distribution and cardiac function: a cross-sectional study.
RMD Open. 2023 Feb;9(1):e002815. doi: 10.1136/rmdopen-2022-002815.
https://pubmed.ncbi.nlm.nih.gov/36828644/ -
Gonçalves Júnior J, Luppino-Assad AP.
Bone within bone in juvenile dermatomyositis
Clin Rheumatol. 2023 Feb 24. doi: 10.1007/s10067-023-06554-3. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36823456/
-
Sherman MA, Kim H, Banschbach K, Brown A, Gewanter HL, Lang B, et al.
Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance.
Pediatr Rheumatol Online J. 2023 Jan 6;21(1):3. doi: 10.1186/s12969-022-00785-5.
https://pubmed.ncbi.nlm.nih.gov/36609397/ -
Gofshteyn J, Mansfield L, Spitznagle J, Balasubramanian P, Cardenas J, Miller T, et al.
Juvenile dermatomyositis disease activity is associated with the expansion of blood B and T-cell memory subsets lacking follicular markers.
Arthritis Rheumatol. 2023 Jan 17. doi: 10.1002/art.42446. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36648920/ -
Curiel RV, Nguyen W, Mamyrova G, Jones D, Ehrlich A, Brindle KA, et al; Abatacept in Dermatomyositis (AID) Trial Investigators.
Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy.
Arthritis Rheumatol. 2023 Jan 19. doi: 10.1002/art.42450. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36657109/ -
Morales M, Alayi TD, Tawalbeh SM, Sydenstricker AV, Spathis R, Kim H, Kanneboyina N, Hathout Y, Rider LG.
Urine proteomics by mass spectrometry identifies proteins involved in key pathogenic pathways in patients with juvenile dermatomyositis.
Rheumatology (Oxford). 2023 Jan 20:kead033. doi: 10.1093/rheumatology/kead033. Epub ahead of prin.
https://pubmed.ncbi.nlm.nih.gov/36661295/
-
Wilkinson MGL, Moulding D, McDonnell TCR, Orford M, Wincup C, Ting JYJ, Otto GW, Restuadi R, Kelberman D, Papadopoulou C, Castellano S, Eaton S, Deakin CT, Rosser EC, Wedderburn LR.
Role of CD14+ monocyte-derived oxidised mitochondrial DNA in the inflammatory interferon type 1 signature in juvenile dermatomyositis
Ann Rheum Dis. 2022 Dec 23:ard-2022-223469. doi: 10.1136/ard-2022-223469. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36564154/ -
Lin TW, Hu YC, Chiang BL.
Characterization of the biomarkers related to the clinical course and outcomes of juvenile dermatomyositis
J Microbiol Immunol Infect. 2022 Dec 16:S1684-1182(22)00288-2. doi: 10.1016/j.jmii.2022.12.007. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36572597/ -
Pepys J, Borchert RJ, Thambirajah N, Daruwalla C, Apostolopoulos D, O'Donovan DG, Ham T, Brierley C.
A rare presentation of rapidly progressing myopathy in an adolescent
Mod Rheumatol Case Rep. 2022 Dec 23:rxac097. doi: 10.1093/mrcr/rxac097. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36562098/ -
Xu H, Wang L, Wei S, Li C, Yuan K.
Using imaging methods to assess severe calcinosis in juvenile dermatomyositis: A case report
Int J Rheum Dis. 2022 Dec 20. doi: 10.1111/1756-185X.14539. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36539990/
-
Sener S, Basaran O, Batu ED, Sag E, Oz S, Talim B, Bilginer Y, Haliloglu G, Ozen S.
Early-onset juvenile dermatomyositis: A tertiary referral center experience and review of the literature.
Semin Arthritis Rheum. 2022 Nov 19;58:152133. doi: 10.1016/j.semarthrit.2022.152133. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36434896/ -
Boros C, McCann L, Simou S, Cancemi D, Ambrose N, Pilkington CA, Cortina-Borja M, Wedderburn LR; JDM Cohort and Biomarker Study (JDCBS).
Juvenile Dermatomyositis: what comes next? Long-term outcomes in childhood myositis from a patient perspective.
Pediatr Rheumatol Online J. 2022 Nov 16;20(1):102. doi:10.1186/s12969-022-00754-y.
https://pubmed.ncbi.nlm.nih.gov/36384526/ -
Fionda L, Lauletta A, Leonardi L, Perez JA, Morino S, Merlonghi G, et al
Muscle MRI in immune-mediated necrotizing myopathy (IMNM): implications for clinical management and treatment strategies.
J Neurol. 2022 Nov 3. doi: 10.1007/s00415-022-11447-7. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36329184/ -
Landon-Cardinal O, Guillaume-Jugnot P, Toquet S, Sbeih N, Rigolet A, Champtiaux N, et al.
JAK inhibitors for the treatment of adult dermatomyositis: A pilot study.
J Am Acad Dermatol. 2022 Nov 8:S0190-9622(22)02983-8. doi: 10.1016/j.jaad.2022.10.055. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36356704/ -
Aggarwal R, Naveen R, Thakare D, Shahi R, Anuja AK, Husain A, Abbasi M, Rathore U, Agarwal V, Gupta L.
Retinal changes in patients with idiopathic inflammatory myopathies: A case-control study in the MyoCite cohort.
Front Med (Lausanne). 2022 Nov 30;9:1065960. doi: 10.3389/fmed.2022.1065960.
https://pubmed.ncbi.nlm.nih.gov/36530925/ -
Moll SA, Platenburg MGJP, Platteel ACM, Vorselaars ADM, Janssen Bonàs M, Kraaijvanger R, et al.
Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases.
PLoS One. 2022 Nov 3;17(11):e0277007. doi: 10.1371/journal.pone.0277007.
https://pubmed.ncbi.nlm.nih.gov/36327336/
-
Bentick G, Fairley J, Nadesapillai S, Wicks I, Day J.
Defining the clinical utility of PET or PET-CT in idiopathic inflammatory myopathies: A systematic literature review.
Semin Arthritis Rheum. 2022 Oct 18;57:152107. doi: 10.1016/j.semarthrit.2022.152107. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36335683/ -
Agud-Dios M, Arroyo-Andres J, Rubio-Muñiz C, Zarco-Olivo C, Calleja-Algarra A, de Inocencio J, Perez SIP
Juvenile dermatomyositis-associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy.
Agud-Dios M, Arroyo-Andres J, Rubio-Muñiz C, Zarco-Olivo C, Calleja-Algarra A, de Inocencio J, Perez SIP.
https://pubmed.ncbi.nlm.nih.gov/36286617/
-
Varnier GC, Consolaro A, Cheng IL, Silva Riveiro A, Pilkington C, Ravelli A.
Experience with the use of mycophenolate mofetil in juvenile idiopathic inflammatory myopathies.
Rheumatology (Oxford). 2022 Aug 5:keac404. doi: 10.1093/rheumatology/keac404.
https://pubmed.ncbi.nlm.nih.gov/35929784/ -
Sherman MA, Graf R, Sabbagh SE, Galindo-Feria AS, Pinal-Fernandez I, Pak K, Kishi T, Flegel WA, Targoff IN, Miller FW, Lundberg IE, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group.
Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features
Rheumatology (Oxford). 2022 Aug 12:keac428. doi: 10.1093/rheumatology/keac428.
https://pubmed.ncbi.nlm.nih.gov/35961028/
-
Huang B, Wang X, Niu Y, Ding Y, Wang X, Tan Q, Li Y, Liu Y, Chi Y, Wang Y, Zhou Z, Li J.
Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis.
Rheumatology (Oxford). 2022 Jul 29:keac399. doi: 10.1093/rheumatology/keac399. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35904570/ -
Mehta P, Aggarwal R, Porter JC, Gunawardena H.
Management of interstitial lung disease (ILD) in myositis syndromes: A practical guide for clinicians.
Best Pract Res Clin Rheumatol. 2022 Jul 12:101769. doi: 10.1016/j.berh.2022.101769. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35840503/ -
Neely J, Ardalan K, Huber A, Kim S; Childhood Arthritis and Rheumatology Research Alliance Investigators.
Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry.
Pediatr Rheumatol Online J. 2022 Jul 19;20(1):50. doi: 10.1186/s12969-022-00709-3.
https://pubmed.ncbi.nlm.nih.gov/35854378/
-
Stingl C, Dvergsten JA, Eng SWM, Yeung RSM, Fritzler MJ, Mason T, Crowson C, Voora D, Reed AM.
Gene Expression Profiles of Treatment Response and Non-Response in Children With Juvenile Dermatomyositis.
ACR Open Rheumatol. 2022 May 26. doi: 10.1002/acr2.11445. Epub ahead of print. PMID: 35616642.
https://pubmed.ncbi.nlm.nih.gov/35616642/ -
Karaca Ö, Güngör M, Sakarya Güneş A, Eser Şimşek I, Anık Y, Kara B.
Angioedema-like presentation as the presenting finding of juvenile myositis and juvenile dermatomyositis in 2 patients.
Int J Rheum Dis. 2022 May;25(5):617-625. doi: 10.1111/1756-185X.14311.
https://pubmed.ncbi.nlm.nih.gov/35238477/
-
Paik JJ, Lubin G, Gromatzky A, Mudd PN Jr, Ponda MP, Christopher-Stine L.
Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review.
Clin Exp Rheumatol. 2022 Jun 28. doi: 10.55563/clinexprheumatol/hxin6o. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35766013/ -
Xiong A, Qiang Y, Cao Y, Shuai Y, Chen H, Xiang Q et al.
The Therapeutic Efficacy and Safety of Intravenous Immunoglobulin in Dermatomyositis and Polymyositis: A Systematic Review and Meta-Analysis.
Mod Rheumatol. 2022 Jun 4:roac057. doi: 10.1093/mr/roac057. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35660927/ -
Turnier JL, Yee CM, Madison JA, Rizvi SM, Berthier CC, Wen F, Kahlenberg JM.
Imaging mass cytometry reveals predominant innate immune signature and endothelial-immune cell interaction in juvenile myositis compared to lupus skin.
Arthritis Rheumatol. 2022 Jun 28. doi: 10.1002/art.42283. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35762881/ -
Mondal S, Barman P, Vignesh P.
Cardiovascular Abnormalities in Juvenile Dermatomyositis: A Scoping Review for the Clinical Rheumatologists.
Front Med (Lausanne). 2022 Jun 24;9:827539. doi: 10.3389/fmed.2022.827539.
https://pubmed.ncbi.nlm.nih.gov/35814777/
-
Scalabrini JC, Schiffenbauer AI, Farhadi PN, Volochayev R, Bayat N, Jansen A, Targoff IN, Miller FW, Rider LG.
Environmental factors associated with juvenile idiopathic inflammatory myopathy clinical and serologic phenotypes.
Pediatr Rheumatol Online J. 2022 Apr 12;20(1):28. doi: 10.1186/s12969-022-00684-9.
https://pubmed.ncbi.nlm.nih.gov/35414090/
-
Oldroyd AGS, Lilleker JB, Amin T, Aragon O, Bechman K, Cuthbert V, et al; British Society for Rheumatology Standards, Audit and Guidelines Working Group.
British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy.
Rheumatology (Oxford). 2022 Mar 31:keac115. doi: 10.1093/rheumatology/keac115. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35355064/ -
Saygin D, Oddis CV.
Glucocorticoids in Myositis: Initiation, Tapering, and Discontinuation.
Curr Rheumatol Rep. 2022 Mar;24(3):47-53. doi: 10.1007/s11926-022-01060-y.
https://pubmed.ncbi.nlm.nih.gov/35275363/ -
Zuo Y, Ye L, Chen F, Shen Y, Lu X, Wang G, Shu X.
Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
Front Immunol. 2022 Mar 7;13:845988. doi: 10.3389/fimmu.2022.845988.
https://pubmed.ncbi.nlm.nih.gov/35320936/ -
Karaca Ö, Güngör M, Sakarya Güneş A, Eser Şimşek I, Anık Y, Kara B.
Angioedema-like presentation as the presenting finding of juvenile myositis and juvenile dermatomyositis in 2 patients.
Int J Rheum Dis. 2022 Mar 3. doi: 10.1111/1756-185X.14311. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35238477/ -
Ray AK, Karmakar P, Chandra A, Ghosh SK, Karmakar PS.
Generalised oedema as a presenting manifestation of inflammatory myopathy.
BMJ Case Rep. 2022 Mar 3;15(3):e248036. doi: 10.1136/bcr-2021-248036.
https://pubmed.ncbi.nlm.nih.gov/35241448/ -
Scofield RH, Lewis VM, Cavitt J, Kurien BT, Assassi S, Martin J, et al.
47XXY and 47XXX in Scleroderma and Myositis.
ACR Open Rheumatol. 2022 Mar 29. doi: 10.1002/acr2.11413. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35352506/
-
McCann LJ, Livermore P, Wilkinson MGL, Wedderburn LR.
Juvenile dermatomyositis. Where are we now?
Clin Exp Rheumatol. 2022 Feb;40(2):394-403. Epub 2022 Feb 7.
https://pubmed.ncbi.nlm.nih.gov/35225221/ -
Stewart JA, Price T, Moser S, Mullikin D, Bryan A.
Progressive, refractory macrophage activation syndrome as the initial presentation of anti-MDA5 antibody positive juvenile dermatomyositis: a case report and literature review.
Pediatr Rheumatol Online J. 2022 Feb 22;20(1):16. doi: 10.1186/s12969-022-00675-w.
https://pubmed.ncbi.nlm.nih.gov/35193600/
-
Witczak BN, Schwartz T, Barth Z, Taraldsrud E, Lund MB, Aaløkken TM, Flatø B, Sjaastad I, Sanner H.
Associations between cardiac and pulmonary involvement in patients with juvenile dermatomyositis-a cross-sectional study.
Rheumatol Int. 2022 Jan 4. doi: 10.1007/s00296-021-05071-3.
https://pubmed.ncbi.nlm.nih.gov/34984516/ -
Deakin CT, Bowes J, Rider LG, Miller FW, Pachman LM, Sanner H, Rouster-Stevens K, Mamyrova G, Curiel R, Feldman BM, Huber AM, Reed AM, Schmeling H, Cook CG, Marshall LR, Wilkinson MGL, Eyre S, Raychaudhuri S, Wedderburn LR.
Association with HLA-DRβ1 position 37 distinguishes juvenile Dermatomyositis from adult-onset myositis.
Hum Mol Genet. 2022 Jan 31:ddac019. doi: 10.1093/hmg/ddac019.
https://pubmed.ncbi.nlm.nih.gov/35094092/
-
Le Voyer T, Gitiaux C, Authier FJ, Bodemer C et al.
JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
Rheumatology (Oxford). 2021 Dec 1;60(12):5801-5808. doi: 10.1093/rheumatology/keab116.
https://pubmed.ncbi.nlm.nih.gov/33576769/ -
Chan Ng PLP, Mopur A, Thiam Goh DY, Babu Ramamurthy M, Chung Lim MT et al.
Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease.
Int J Rheum Dis. 2021 Dec 9. doi: 10.1111/1756-185X.14258. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34882988/ -
Schänzer A, Rager L, Dahlhaus I, Dittmayer C, Preusse C, Della Marina A et al.
Morphological Characteristics of Idiopathic Inflammatory Myopathies in Juvenile Patients.
Cells. 2021 Dec 30;11(1):109. doi: 10.3390/cells11010109.
https://pubmed.ncbi.nlm.nih.gov/35011672/ -
Marrani E, Abu Rumeileh A, Vincenza Mastrolia M, Maccora I, Pagnini I, Simonini G.
A systematic review on biological therapies in juvenile idiopathic inflammatory myopathies: an evidence gap in precision medicine.
Clin Exp Rheumatol. 2021 Dec 14. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34905479/ -
Wu W, Xu W, Sun W, Zhang D, Zhao J, Luo Q et al.
Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study.
Rheumatology (Oxford). 2021 Dec 24;61(1):230-239. doi: 10.1093/rheumatology/keab305.
https://pubmed.ncbi.nlm.nih.gov/33764398/ -
My Ly NT, Ma N, Ueda-Hayakawa I, Hong Nguyen CT, Anada R, Okamoto H, Fujimoto M.
Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1γ antibodies.
J Dermatol Sci. 2021 Dec;104(3):177-184. doi: 10.1016/j.jdermsci.2021.10.003. Epub 2021 Oct 13.
https://pubmed.ncbi.nlm.nih.gov/34772582/
-
Karasawa R, Yudoh K, Sato T, Tanaka M, Tamaki M, Sabbagh SE, O'Hanlon TP, Noroozi-Farhadi P, Targoff IN, Flegel WA, Mammen AL, Miller FW, Hicar MD, Rider LG, Jarvis JN
Association of Anti-HSC70 Autoantibodies with Cutaneous Ulceration and Severe Disease in Juvenile Dermatomyositis.
Rheumatology (Oxford). 2021 Nov 13:keab846. doi: 10.1093/rheumatology/keab846. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34791087/ -
Astley C, Sieczkowska SM, Marques IG, Ihara BP, Lindoso L, Lavorato SSM, Campos LMA, Pereira RMR, Elias AM, Aikawa NE, Kozu K, Iraha AY, Franco TC, Roschel H, Queiroz LB, Polanczyk GV, Silva CA, Gualano B.
Home-based exercise program for adolescents with juvenile dermatomyositis quarantined during COVID-19 pandemic: a mixed methods study.
Pediatr Rheumatol Online J. 2021 Nov 13;19(1):159. doi: 10.1186/s12969-021-00646-7.
https://pubmed.ncbi.nlm.nih.gov/34774060/ -
Gargh K, Al-Abadi E, Low S, Harrison K, Coles W, Davis P, Johnson K.
Juvenile Dermatomyositis Magnetic Resonance Imaging Score (JIS) does not correlate with criteria for clinically inactive disease: a single-centre retrospective evaluation.
Rheumatol Int. 2021 Nov 18. doi: 10.1007/s00296-021-05049-1. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34796407/
-
Stenzel W, Goebel HH, Bader-Meunier B, Gitiaux C.
Inflammatory myopathies in childhood.
Neuromuscul Disord. 2021 Oct;31(10):1051-1061. doi: 10.1016/j.nmd.2021.08.007. Epub 2021 Oct 9.
https://pubmed.ncbi.nlm.nih.gov/34736626/ -
Bagri NK.
Autoantibodies in Juvenile Dermatomyositis: Need to Bridge the Bench and Bedside Gap.
Indian J Pediatr. 2021 Oct 5. doi: 10.1007/s12098-021-03971-7. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34609653/ -
Konishi R, Tanaka R, Inoue S, Ichimura Y, Nomura T, Okiyama N.
Evaluation of apremilast, an oral phosphodiesterase 4 inhibitor, for refractory cutaneous dermatomyositis: A phase 1b clinical trial.
J Dermatol. 2021 Oct 3. doi: 10.1111/1346-8138.16179. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34605053/
-
Ll Wilkinson MG, Deakin CT, Papadopoulou C, Eleftheriou D, Wedderburn LR.
JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology.
Pediatr Rheumatol Online J. 2021 Sep 25;19(1):146. doi: 10.1186/s12969-021-00637-8.
https://pubmed.ncbi.nlm.nih.gov/34563217/ -
Wilkinson MGL, Wu W, O'Brien K, Deakin CT, Wedderburn LR, Livermore P.
A survey to understand the feelings towards and impact of COVID-19 on the households of juvenile dermato myositis patients from a parent or carer perspective.
Rheumatol Adv Pract. 2021 Sep 13;5(3):rkab058. doi: 10.1093/rap/rkab058. eCollection 2021.
https://pubmed.ncbi.nlm.nih.gov/34541451/
-
Rodero MP, Pelleau S, Welfringer-Morin A; FJDM study group, Duffy D, Melki I, Bader-Meunier B; FJDM Study group, et al.
Onset and Relapse of Juvenile Dermatomyositis Following Asymptomatic SARS-CoV-2 Infection.
J Clin Immunol. 2021 Aug 23:1-3. doi: 10.1007/s10875-021-01119-y. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34426906/ -
Liquidano-Perez E, García-Romero MT, Yamazaki-Nakashimada M, Maza-Morales M, Rivas-Calderón MK, Bayardo-Gutierrez B, Pardo-Díaz E, Scheffler-Mendoza SC.
Juvenile Dermatomyositis Triggered by SARS-CoV-2.
Pediatr Neurol. 2021 Aug;121:26-27. doi: 10.1016/j.pediatrneurol.2021.05.011.
https://pubmed.ncbi.nlm.nih.gov/34126319/ -
Egeli BH, Ergun S, Cetin A, Gursoy YK, Ugurlu S.
Rituximab as a glucocorticoid-sparing agent in idiopathic inflammatory myopathies: a retrospective single-center cohort study.
Clin Rheumatol. 2021 Aug 13. doi: 10.1007/s10067-021-05871-9. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34387760/ -
Xu W, Wu W, Zhang D, Chen Z, Tao X, Zhao J, Wang K, Wang X, Zheng Y, Ye S.
A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis.
Sci Rep. 2021 Aug 23;11(1):17070. doi: 10.1038/s41598-021-96292-w.
https://pubmed.ncbi.nlm.nih.gov/34426622/ -
Schildt EE, De Ranieri D.
Anasarca as the presenting symptom of juvenile dermatomyositis: a case series
Pediatr Rheumatol Online J. 2021 Aug 13;19(1):120. doi: 10.1186/s12969-021-00604-3.
https://pubmed.ncbi.nlm.nih.gov/34389019/ -
Johnson D, van Eeden C, Moazab N, Redmond D, Phan C, Keeling S, Gniadecki R, Cohen Tervaert JW, Osman M.
Nailfold Capillaroscopy Abnormalities Correlate With Disease Activity in Adult Dermatomyositis.
Front Med (Lausanne). 2021 Aug 10;8:708432. doi: 10.3389/fmed.2021.708432.
https://pubmed.ncbi.nlm.nih.gov/34447769/
-
Papadopoulou C, Hong Y, Krol P, Al Obaidi M, Pilkington C, Wedderburn LR, Brogan PA, Eleftheriou D.
The Vasculopathy of Juvenile Dermatomyositis: Endothelial Injury, Hypercoagulability, and Increased Arterial Stiffness.
Arthritis Rheumatol. 2021 Jul;73(7):1253-1266. doi: 10.1002/art.41639. Epub 2021 May 28. PMID: 33393715.
https://pubmed.ncbi.nlm.nih.gov/33393715/ -
Rietveld A, Wienke J, Visser E, Vree Egberts W, Schlumberger W, van Engelen B, van Royen-Kerkhof A, Lu H, Wedderburn L, Saris C, Tansley S, Pruijn G; Juvenile Dermatomyositis Research Group and the Dutch Myositis Consortium.
Anti-Cytosolic 5'-Nucleotidase 1A Autoantibodies Are Absent in Juvenile Dermatomyositis.
Arthritis Rheumatol. 2021 Jul;73(7):1329-1333. doi: 10.1002/art.41660. Epub 2021 May 18. PMID: 33497020.
https://pubmed.ncbi.nlm.nih.gov/33497020/
-
Megan Mariko Perron, Natalia Vasquez-Canizares, Gabriel Tarshish, Dawn M Wahezi.
Myositis autoantibodies in a racially diverse population of children with idiopathic inflammatory myopathies.
Pediatr Rheumatol Online J. 2021 Jun 12;19(1):92. doi: 10.1186/s12969-021-00574-6.
https://pubmed.ncbi.nlm.nih.gov/34118936/ -
Zhang J, Xue Y, Liu X, Kuang W, Tan X, Li C, Li C.
Identification of 4 subgroups in juvenile dermatomyositis by principal component analysis-based cluster análisis
Clin Exp Rheumatol. 2021 Jun 22. Online ahead of print
https://pubmed.ncbi.nlm.nih.gov/34251318/
-
Neely J, Shalen J, Sturrock H, Kim S; Childhood Arthritis and Rheumatology Research Alliance Investigators.
Access to Care and Diagnostic Delays in Juvenile Dermatomyositis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. ACR Open Rheumatol. 2021 May;3(5):349-354. oi:10.1002/acr2.11246
https://pubmed.ncbi.nlm.nih.gov/33932146/ -
Julie J Paik, Livia Casciola-Rosen, Joseph Yusup Shin, Jemima Albayda, Eleni Tiniakou et al.
Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.
Arthritis Rheumatol. 2021 May;73(5):858-865. doi: 10.1002/art.41602. Epub 2021 Mar 24.
https://pubmed.ncbi.nlm.nih.gov/33258553/ -
Kishi T, Warren-Hicks W, Bayat N, Targoff IN, Huber AM, Ward MM, Rider LG, with the Childhood Myositis Heterogeneity Study Group.
Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis.
Rheumatology (Oxford). 2021 May 14;60(5):2134-2145. doi: 10.1093/rheumatology/keaa371.
https://pubmed.ncbi.nlm.nih.gov/33067611/
-
Marstein HS, Godang K, Flatø B, Sjaastad I, Bollerslev J, Sanner H.
Bone mineral density and explanatory factors in children and adults with juvenile dermatomyositis at long term follow-up; a cross sectional study.
Pediatr Rheumatol Online J. 2021 Apr 26;19(1):56.
https://pubmed.ncbi.nlm.nih.gov/33902632/
-
Paudyal A, Zheng M, Lyu L, Thapa C, Gong S, Yang Y, Lyu X.
JAK-inhibitors for dermatomyositis: A concise literature review.
Dermatol Ther. 2021 Mar 13:e14939. doi: 10.1111/dth.14939. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/33713527/ -
Takanashi S, Kaneko Y, Takeuchi T.
Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: a literature review.
Mod Rheumatol. 2021 Mar 26:1-12. doi: 10.1080/14397595.2021.1906505. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/33769925/ -
Doudouliaki T, Papadopoulou C, Deakin CT.
Use of Rescue Therapy with IVIG or Cyclophosphamide in Juvenile Myositis.
Curr Rheumatol Rep. 2021 Mar 8;23(4):24. doi: 10.1007/s11926-021-00990-3.
https://pubmed.ncbi.nlm.nih.gov/33686540/ -
De Lorenzo R, Sciorati C, Monno A, Cavalli S, Bonomi F, Tronci S, Previtali S, Rovere-Querini P.
Begelomab for severe refractory dermatomyositis: A case report.
Medicine (Baltimore). 2021 Mar 5;100(9):e24372.
https://pubmed.ncbi.nlm.nih.gov/33655912/ -
Rodríguez-Tejero A, López-Espadafor B, Montero-Vílchez T, Sánchez-Díaz M, Arias-Santiago S, Molina-Leyva A.
Treatment challenges in clinically amyopathic dermatomyositis: A case series and review of new therapeutic options for skin involvement.
Dermatol Ther. 2021 Mar 14:e14942. doi: 10.1111/dth.14942. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/33719170/ -
Mehta P, Machado PM, Gupta L.
Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry.
Rheumatol Int. 2021 Mar 27:1-16. doi: 10.1007/s00296-021-04819-1. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/33774723/ -
Wu W, Xu W, Sun W, Zhang D, Zhao J, Luo Q, et al.
Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study.
Rheumatology (Oxford). 2021 Mar 25:keab305. doi: 10.1093/rheumatology/keab305. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/33764398/ -
Albayda J, Mecoli C, Casciola-Rosen L, Danoff SK, Lin CT, Hines D, et al.
A North American Cohort of Anti-SAE Dermatomyositis: Clinical Phenotype, Testing, and Review of Cases.
ACR Open Rheumatol. 2021 Mar 28. doi: 10.1002/acr2.11247. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/33774928/ -
Kishi T, Tani Y, Okiyama N, Mizuochi K, Ichimura Y, Harigai M, Nagata S, Miyamae T.
Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease - a case report.
Pediatr Rheumatol Online J. 2021 Mar 19;19(1):34. doi: 10.1186/s12969-021-00532-2
https://pubmed.ncbi.nlm.nih.gov/33740993/
-
Voyer TL, Gitiaux C, Authier FJ, Bodemer C, Melki I, Quartier P, Aeschlimann F, Isapof A, Herbeuval JP, Bondet V, Charuel JL, Frémond ML, Duffy D, Rodero MP, Bader-Meunier B.
JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
Rheumatology (Oxford). 2021 Feb 12:keab116. doi: 10.1093/rheumatology/keab116.
https://pubmed.ncbi.nlm.nih.gov/33576769/ -
Varnier GC, Consolaro A, Maillard S, Pilkington C, Ravelli A.
Comparison of treatments and outcomes of children with juvenile dermatomyositis followed at two European tertiary care referral centers.
Rheumatology (Oxford). 2021 Feb 2:keab089. doi: 10.1093/rheumatology/keab089.
https://pubmed.ncbi.nlm.nih.gov/33528490/ -
Yamasaki Y, Kobayashi N, Akioka S, Yamazaki K, Takezaki S, Nakaseko H, Ohara A, Nishimura K, Nishida Y, Sato S, Kishi T, Hashimoto M, Mori M, Okazaki Y, Kuwana M, Ohta A.
Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicenter study.
Rheumatology (Oxford). 2021 Feb 5:keab108. doi: 10.1093/rheumatology/keab108.
https://pubmed.ncbi.nlm.nih.gov/33576399/ -
Kul Cinar O, Papadopoulou C, Pilkington CA.
Treatment of Calcinosis in Juvenile Dermatomyositis.
Curr Rheumatol Rep. 2021 Feb 8;23(2):13. doi: 10.1007/s11926-020-00974-9.
https://pubmed.ncbi.nlm.nih.gov/33555459/ -
Platter M, Pugmire B, Patel R.
Resolution of calcinosis using bisphosphonates in overlap syndrome - a case report.
BMC Rheumatol. 2021 Feb 26;5(1):6. doi: 10.1186/s41927-021-00176-5.
https://pubmed.ncbi.nlm.nih.gov/33632332/
-
Wang X, Ding Y, Zhou Z, Hou J, Xu Y, Li J.
Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children.
Pediatr Rheumatol Online J. 2021 Jan 6;19(1):6. doi: 10.1186/s12969-020-00492-z. PMID: 33407621; PMCID: PMC7788734.
https://pubmed.ncbi.nlm.nih.gov/33407621/ -
Papadopoulou C, Hong Y, Krol P, Al Obaidi M, Pilkington C, Wedderburn LR, Brogan PA, Eleftheriou D.
The Vasculopathy of Juvenile Dermatomyositis: endothelial injury, hypercoagulability, and increased arterial stiffness.
Arthritis Rheumatol. 2021 Jan 4. doi: 10.1002/art.41639. Epub ahead of print. PMID: 33393715.
https://pubmed.ncbi.nlm.nih.gov/33393715/ -
Rietveld A, Wienke J, Visser E, Vree Egberts W, Schlumberger W, van Engelen B, van Royen-Kerkhof A, Lu H, Wedderburn L, Saris C, Tansley S, Pruijn G; Juvenile Dermatomyositis Research Group.
Anti-cN-1A autoantibodies are absent in juvenile dermatomyositis.
Arthritis Rheumatol. 2021 Jan 26. doi: 10.1002/art.41660. Epub ahead of print. PMID: 33497020.
https://pubmed.ncbi.nlm.nih.gov/33497020/
-
Gupta L, Naveen R, Gaur P, Agarwal V, Aggarwal R.
Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis.
Semin Arthritis Rheum. 2020 Dec 22;51(1):113-120
https://pubmed.ncbi.nlm.nih.gov/33360322/ -
Sag E, Demir S, Bilginer Y, Talim B, Haliloglu G, Topaloglu H, Ozen S.
Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis.
Semin Arthritis Rheum. 2020 Dec 21;51(1):95-100
https://pubmed.ncbi.nlm.nih.gov/33360233/ -
Hou C, Durrleman C, Periou B, Barnerias C, Bodemer C, Desguerre I, Quartier P, Melki I, Rice GI, Rodero MP, Charuel JL, Relaix F, Bader-Meunier B, Authier FJ, Gitiaux C.
From diagnosis to prognosis: Revisiting the meaning of muscle ISG15 overexpression in juvenile inflammatory myopathies.
Arthritis Rheumatol. 2020 Dec 14. doi: 10.1002/art.41625
https://pubmed.ncbi.nlm.nih.gov/33314705/ -
Dalakas MC.
Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications.
Acta Myol. 2020 Dec 1;39(4):289-301
https://pubmed.ncbi.nlm.nih.gov/33458584/ -
Prasad KK, Bhatia MS, Sirsath NT.
Dermatomyositis: Look beyond skin.
J Cancer Res Ther. 2020 Dec;16(Supplement):S251-S252
https://pubmed.ncbi.nlm.nih.gov/33380693/ -
Wang A, Morgan GA, Paller AS, Pachman LM.
Skin Disease is More Recalcitrant Than Muscle Disease: A Long-Term Prospective Study of 184 Children with Juvenile Dermatomyositis.
J Am Acad Dermatol. 2020 Dec 23:S0190-9622(20)33223-0
https://pubmed.ncbi.nlm.nih.gov/33359787/ -
Sag E, Demir S, Bilginer Y, Talim B, Haliloglu G, Ozen S.
Validation of the EULAR/ACR 2017 idiopathic inflammatory myopathy classification criteria in juvenile dermatomyositis patients.
Clin Exp Rheumatol. 2020 Dec 4
https://pubmed.ncbi.nlm.nih.gov/33337999/ -
Khojah A, Liu V, Savani SI, Morgan G, Shore R, Bellm J, Pachman LM.
Studies of 96 children with Juvenile Dermatomyositis: P155/140, is associated with loss of nailfold capillaries, but not generalized lipodystrophy.
Arthritis Care Res (Hoboken). 2020 Dec 8. doi: 10.1002/acr.24535
https://pubmed.ncbi.nlm.nih.gov/33290639/ -
Sözeri B, Demir F.
A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate.
Rheumatology (Oxford). 2020 Dec 1;59(12):e140-e141
https://pubmed.ncbi.nlm.nih.gov/32754736/
-
Rosina S, Varnier GC, Pistorio A, Pilkington C, Maillard S, Civino A, Tsitsami E, Bracaglia C, Jelusic M, Cespedes-Cruz A, Espada G, Cimaz R, Coutillault G, Joos R, Quartier P, Rao AP, Malattia C, Ruperto N, Consolaro A, Ravelli A; Pediatric Rheumatology International Trials Organization (PRINTO).
Development and testing of reduced versions of the MMT-8 in juvenile dermatomyositis.
J Rheumatol. 2020 Nov 15:jrheum.200543. doi: 10.3899/jrheum.200543
https://pubmed.ncbi.nlm.nih.gov/33191283/
-
Sag E, Kale G, Haliloglu G, Bilginer Y, Akcoren Z, Orhan D, Gucer S, Topaloglu H, Ozen S, Talim B.
Inflammatory milieu of muscle biopsies in juvenile dermatomyositis
Rheumatol Int. 2020 Oct 26. doi: 10.1007/s00296-020-04735-w. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/33106894/ - Yu Z, Wang L, Quan M, Zhang T, Song H.
Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review.
Rheumatology (Oxford). 2020 Oct 7:keaa558. doi: 10.1093/rheumatology/keaa558. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/33024992/ -
Quintana-Ortega C, Remesal A, Ruiz de Valbuena M, de la Serna O, Laplaza-González M, Álvarez-Rojas E, Udaondo C, Alcobendas R, Murias S.
Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Mod Rheumatol Case Rep. 2020 Oct 20:1-7. doi: 10.1080/24725625.2020.1832755. Online ahead of print
https://pubmed.ncbi.nlm.nih.gov/33019894/ -
Tawalbeh SM, Marin W, Morgan GA, Dang UJ, Hathout Y, Pachman LM.
Serum protein biomarkers for juvenile dermatomyositis: a pilot study.
BMC Rheumatol. 2020 Oct 1;4:52. doi: 10.1186/s41927-020-00150-7. eCollection 2020
https://pubmed.ncbi.nlm.nih.gov/33015544/ -
Horn S, Minden K, Speth F, Schwarz T, Dressler F, Grösch N, Haas JP, Hinze C, Horneff G, Hospach A, Kallinich T, Klotsche J, Köstner K, Meisel C, Niewerth M, Oommen PT, Schütz C, Weller-Heinemann F, Unterwalder N, Sengler C.
Myositis-specific autoantibodies and their associated phenotypes in juvenile dermatomyositis: data from a German cohort.
Clin Exp Rheumatol. 2020 Oct 29. Online ahead of print
https://pubmed.ncbi.nlm.nih.gov/33124555/ -
Kishi T, Warren-Hicks W, Bayat N, Targoff IN, Huber AM, Ward MM, Rider LG; with the Childhood Myositis Heterogeneity Study Group.
Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis.
Rheumatology (Oxford). 2020 Oct 17:keaa371. doi: 10.1093/rheumatology/keaa371. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/33067611/
-
Diniz MFR, Kozu KT, Elias AM, Lianza AC, Sawamura KSS, Menezes CRB, Ferreira JCOA, Silva CA, Leal GN.
Echocardiographic study of juvenile dermatomyositis patients: new insights from speckle-tracking-derived strain.
BMJ Case Rep. 2020 Sep Clin Rheumatol. 2020 Sep 28. doi: 10.1007/s10067-020-05418-4. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/32989504/ - Ishikawa Y, Kasuya T, Fujiwara M, Kita Y.
Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: A case report.
Medicine (Baltimore). 2020 Sep 11;99(37):e21943. doi: 10.1097/MD.0000000000021943.
https://pubmed.ncbi.nlm.nih.gov/32925726/ -
Navarro-Navarro I, Jiménez-Gallo D, Rodríguez-Mateos ME, Rodríguez-Hernández C, Linares-Barrios M.
Treatment of refractory anti-NXP2 and anti-TIF1γ dermatomyositis with tofacitinib.
J Dtsch Dermatol Ges. 2020 Sep 10. doi: 10.1111/ddg.14276. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/32909360/ -
Ohmura SI, Yamabe T, Naniwa T.
Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies.
Mod Rheumatol Case Rep. 2020 Sep 14:1-6. doi: 10.1080/24725625.2020.1816674. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/32867615/ -
Li R, Zhu WJ, Wang F, Tang X, Luo F.
AST/ALT ratio as a predictor of mortality and exacerbations of PM/DM-ILD in 1 year-a retrospective cohort study with 522 cases.
Arthritis Res Ther. 2020 Sep 20;22(1):202.
https://pubmed.ncbi.nlm.nih.gov/32950060/ -
Xing X, Li A, Li C.
Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis.
Respir Med. 2020 Sep 1;172:106134. doi: 10.1016/j.rmed.2020.106134. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/32905890/ -
Aljabban J, Syed S, Syed S, Rohr M, Weisleder N, McElhanon KE, Hasan L, Safeer L, Hoffman K, Aljabban N, Mukhtar M, Adapa N, Allarakhia Z, Panahiazar M, Neuhaus I, Kim S, Hadley D, Jarjour W
Investigating genetic drivers of dermatomyositis pathogenesis using meta-analysis.
Heliyon. 2020 Sep 24;6(9):e04866. doi: 10.1016/j.heliyon.2020.e04866.
https://pubmed.ncbi.nlm.nih.gov/33015383/ -
Ardalan K, Adeyemi O, Wahezi DM, Caliendo AE, Curran ML, Neely J, Kim S, Correll CK, Brunner EJ, Knight AM.
Parent Perspectives on Addressing Emotional Health for Children and Young Adults with Juvenile Myositis.
Arthritis Care Res (Hoboken). 2020 Sep 28. doi: 10.1002/acr.24466. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/32986925/
-
Gullapalli K, Goldzweig O, Nanda K, Chekka R, Berry S, Bukulmez H.
Juvenile Dermatomyositis (JDM) Complicated by Thrombotic Thrombocytopenic Purpura (TTP) and Purtscher's Retinopathy Responsive to Rituximab: Case Report and Literature Review.
Front Pediatr. 2020 Aug 4;8:436. doi: 10.3389/fped.2020.00436.
https://pubmed.ncbi.nlm.nih.gov/32850549/ - Kim H, Dill S, O'Brien M, Vian L, Li X, Manukyan M, Jain M, Adeojo LW, George J, Perez M, Grom AA, Sutter M, Feldman BM, Yao L, Millwood M, Brundidge A, Pichard DC, Cowen EW, Shi Y, Lu S, Tsai WL, Gadina M, Rider LG, Colbert RA.
Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.
Ann Rheum Dis. 2020 Aug 25:annrheumdis-2020-218690. doi: 10.1136/annrheumdis-2020-218690.
https://pubmed.ncbi.nlm.nih.gov/32843325/ - Farah C, Tabesh OA, Okais J, Hajjar A, Haddad A.Pan
Cricoarytenoid joint arthritis: a possible complication of dermatomyositis.
Afr Med J. 2020 Jun 9;36:74. doi: 10.11604/pamj.2020.36.74.18891. eCollection 2020.
https://pubmed.ncbi.nlm.nih.gov/32774633/
-
Zhu DX, Qiao JJ, Fang H.
Macrophage activation syndrome as a complication of dermatomyositis: A case report.
World J Clin Cases. 2020 Jun 6;8(11):2339-2344. doi: 10.12998/wjcc.v8.i11.2339.
https://pubmed.ncbi.nlm.nih.gov/32548165/ -
Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, Miller FW, Milisenda JC, Grau-Junyent JM, Selva-O'Callaghan A, Carrion-Ribas C, Paik JJ, Albayda J, Christopher-Stine L, Lloyd TE, Corse AM, Mammen AL.
Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis.
Ann Rheum Dis. 2020 Jun 16:annrheumdis-2019-216599. doi: 10.1136/annrheumdis-2019-216599
https://pubmed.ncbi.nlm.nih.gov/32546599/ -
Pender TM, Patel AM, Rosenkranz ME.
Efficacy of Repository-Corticotropin Injection (Acthar) in Refractory Juvenile Dermatomyositis: A Case Series.
J Clin Rheumatol. 2020 Jun 4. doi: 10.1097/RHU.0000000000001422.
https://pubmed.ncbi.nlm.nih.gov/32501940/ -
Swafford C, Roach ES.
Juvenile Dermatomyositis and the Inflammatory Myopathies.
Semin Neurol. 2020 Jun;40(3):342-348. doi: 10.1055/s-0040-1705120.
https://pubmed.ncbi.nlm.nih.gov/32252099/ -
Chung MP, Richardson C, Kirakossian D, Orandi AB, Saketkoo LA, Rider LG, Schiffenbauer A, von Mühlen CA, Chung L; International Myositis Assessment; Clinical Studies Group (IMACS) Calcinosis Scientific Interest Group.
Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis.
Autoimmun Rev. 2020 Jun;19(6):102533. doi: 10.1016/j.autrev.2020.102533.
https://pubmed.ncbi.nlm.nih.gov/32234404/
- Ghosh R, Roy D, Dubey S, Abdelrahman K, Dey AK, Chatterjee S, Lahiri D, Ray BK.
Juvenile dermatomyositis presenting as complete heart block in a 10-year-old girl.
Paediatr Int Child Health. 2020 May 19:1-4.
https://doi.org/10.1080/20469047.2020.1765123 - Swafford C, Roach ES.
Juvenile Dermatomyositis and the Inflammatory Myopathies.
Semin Neurol. 2020 Apr 6. doi: 10.1055/s-0040-1705120. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/32252099 - Liu K, Tomlinson G, Reed AM, Huber AM, Saarela O, Bout-Tabaku SM, Curran M, Dvergsten JA, Eberhard BA, Jung LK, Kim S, Ringold S, Rouster-Steven KA, Tesher M, Wahezi DM, Feldman BM; CARRA Registry Investigators
Pilot study of the juvenile dermatomyositis consensus treatment plans: a CARRA Registry study.
J Rheumatol. 2020 Apr 1:jrheum.190494. doi: 10.3899/jrheum.190494. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/32238513
- Wienke J, Pachman LM, Morgan GA, Yeo JG, Amoruso MC, Hans V, Kamphuis SSM, Hoppenreijs EPAH, Armbrust W, van den Berg JM, Hissink Muller PCE, Gelderman KA, Arkachaisri T, van Wijk F, van Royen-Kerkhof A.
Endothelial and inflammatory biomarker profile at diagnosis reflects clinical heterogeneity of juvenile dermatomyositis and is prognostic for response to treatment in two independent cohorts.Arthritis Rheumatol. 2020 Feb 26. doi: 10.1002/art.41236.
https://www.ncbi.nlm.nih.gov/pubmed/32103637 - Zhong D, Wu C, Bai J, Xu D, Zeng X, Wang Q.
Co-expression network analysis reveals the pivotal role of mitochondrial dysfunction and interferon signature in juvenile dermatomyositis.PeerJ. 2020 Feb 18;8:e8611. doi: 10.7717/peerj.8611. eCollection 2020.
https://www.ncbi.nlm.nih.gov/pubmed/32110496
- Tory H, Zurakowski D, Kim S; CARRA Juvenile Dermatomyositis Quality Measures Workgroup for the CARRA Registry Investigators.
Patient and physician discordance of global disease assessment in juvenile dermatomyositis: findings from the Childhood Arthritis & Rheumatology Research Alliance Legacy Registry.
Pediatr Rheumatol Online J. 2020 Jan 15;18(1):5. doi: 10.1186/s12969-020-0402-x.
https://www.ncbi.nlm.nih.gov/pubmed/31941511 - Besnard C, Gitiaux C, Girard M, Galmiche-Rolland L, Talbotec C, Quartier P, Bodemer C, Berteloot L, Bader-Meunier B.
Severe Abdominal Manifestations in Juvenile Dermatomyositis. - J Pediatr Gastroenterol Nutr. 2020 Feb;70(2):247-251. doi: 10.1097/MPG.0000000000002575.
https://www.ncbi.nlm.nih.gov/pubmed/31978027
- Hou J1, Zhou ZX, Li JG, Xu YJ, Ding YC.
Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review
Zhonghua Er Ke Za Zhi. 2019 Dec 2;57(12):928-933.
https://www.ncbi.nlm.nih.gov/pubmed/31795559 - Li D, Tansley SL.
Juvenile Dermatomyositis-Clinical Phenotypes.
Curr Rheumatol Rep. 2019 Dec 11;21(12):74.
https://www.ncbi.nlm.nih.gov/pubmed/31828535 - Neely J, Kim S.
Advances Toward Precision Medicine in Juvenile Dermatomyositis.
Curr Rheumatol Rep. 2019 Dec 7;21(12):73. doi: 10.1007/s11926-019-0873-2
https://www.ncbi.nlm.nih.gov/pubmed/31813083 - Sharma A, Gupta A, Rawat A, Suri D, Singh S.
Long-term outcome in children with juvenile dermatomyositis: A single-center study from north India.
Int J Rheum Dis. 2019 Dec 3. doi: 10.1111/1756-185X.13759.
https://www.ncbi.nlm.nih.gov/pubmed/31793219
- Oldroyd A, Little MA, Dixon W, Chinoy H.
A review of accelerometer-derived physical activity in the idiopathic inflammatory myopathies
BMC Rheumatol. 2019 Oct 21;3:41. doi: 10.1186/s41927-019-0088-1. eCollection 2019.
https://www.ncbi.nlm.nih.gov/pubmed/31660533 - Gitiaux C, Bondet V, Bekaddour N, Nusbaum P, Hubas A, Melki I, Bodemer C, Quartier P, Desguerre I, Crow YJ, Herbeuval JP, Duffy D, Bader Meunier B, Rodero MP.
Inhibition of IFNα secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technology
Rheumatology (Oxford). 2019 Oct 30. pii: kez508. doi: 10.1093/rheumatology/kez508. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/31665500
- Nordal E, Pistorio A, Rygg M, Giancane G, Maghnie M, Di Iorgi N, Flemming K, Hofer M, Melo-Gomes JA, Bica BERG, Brunner J, Dannecker G, Gerloni V, Harjacek M, Huppertz HI, Pratsidou-Gertsi P, Nielsen S, Stanevicha V, Ten Cate R, Vougiouka O, Pastore S, Simonini G, Ravelli A, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).
Growth and puberty in juvenile dermatomyositis: a longitudinal cohort study.
Arthritis Care Res (Hoboken). 2019 Sep 10. doi: 10.1002/acr.24065. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/31507092 - Wu JQ, Lu MP, Reed AM.
Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.
World J Pediatr. 2019 Sep 26. doi: 10.1007/s12519-019-00313-8. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/31556011
- Duvvuri B, Pachman LM, Morgan G, Khojah AM, Klein-Gitelman M, Curran ML, Doty S, Lood C.
Neutrophil Extracellular Traps in Tissue and Periphery in Juvenile Dermatomyositis.
Arthritis Rheumatol. 2019 Aug 12. doi: 10.1002/art.41078.
https://www.ncbi.nlm.nih.gov/pubmed/31403247 - Patwardhan A, Spencer CH.
Biologics in refractory myositis: experience in juvenile vs. adult myositis; part II: emerging biologic and other therapies on the horizon.
Pediatr Rheumatol Online J. 2019 Aug 20;17(1):56.
https://www.ncbi.nlm.nih.gov/pubmed/31429786
- Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG, Mammen AL.
Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis.
Ann Rheum Dis. 2019 Jul;78(7):988-995
https://ard.bmj.com/content/78/7/988 - Rosina S, Consolaro A, van Dijkhuizen P, Pistorio A, Camilla Varnier G, Bovis F et al.
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis.
Rheumatology (Oxford). 2019 Jul;58(7):1196-1205.
https://doi.org/10.1093/rheumatology/key421 - Leclair V, Galindo-Feria AS, Dastmalchi M, Holmqvist M, Lundberg IE.
Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study.
Rheumatology (Oxford). 2019 Jul 1;58(7):1214-1220.
https://www.ncbi.nlm.nih.gov/pubmed/30690633 - Rothwell S, Chinoy H, Lamb JA, Miller FW, Rider LG, Wedderburn LR, et al; Myositis Genetics Consortium (MYOGEN).
Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups.
Ann Rheum Dis. 2019 Jul;78(7):996-1002.
https://www.ncbi.nlm.nih.gov/pubmed/31138531 - Wilkinson MGL, Radziszewska A, Wincup C, Ioannou Y, Isenberg DA, Manson JJ, Jury EC.
Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies.
Rheumatology (Oxford). 2019 Jul 10. pii: kez252. doi: 10.1093/rheumatology/kez252. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/31292651
- Tsaltskan V, Aldous A, Serafi S, Yakovleva A, Sami H, Mamyrova G, Targoff IN, Schiffenbauer A, Miller FW, Simmens SJ, Curiel R, Jones OY, Rider LG.
Long-term outcomes in Juvenile Myositis patients.
Semin Arthritis Rheum. 2019 Jun 28. pii: S0049-0172(19)30136-2. doi: 10.1016/j.semarthrit.2019.06.014. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/31303436
- Mizuta M, Shimizu M, Inoue N, Nakagishi Y, Yachie A
Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome.
Cytokine. 2019 Apr 2;119:182-187.
https://www.ncbi.nlm.nih.gov/pubmed/30952065
- Chamseddin B, Marks E, Dominguez A, Wysocki C, Vandergriff T.
Refractory Macrophage Activation Syndrome in the setting of Adult Onset Still's Disease with Hemophagocytic Lymphohistiocytosis Detected on Skin Biopsy treated with Canakinumab and Tacrolimus.
J Cutan Pathol. 2019 Mar 30. doi: 10.1111/cup.13466. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/30927277 - Papadopoulou C, Hong Y, Omoyinmi E, Brogan PA, Eleftheriou D.
Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.
Brain. 2019 Mar 1;142(3):e8.
https://www.ncbi.nlm.nih.gov/pubmed/30715143 - Pinto B, Janardana R, Nadig R, Mahadevan A, Bhatt AS, Raj JM, Shobha V.
Comparison of the 2017 EULAR/ACR criteria with Bohan and Peter criteria for the classification of idiopathic inflammatory myopathies.
Clin Rheumatol. 2019 Mar 22. doi: 10.1007/s10067-019-04512-6. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/30903308 - Ukichi T, Yoshida K, Matsushima S, Kawakami G, Noda K, Furuya K, Kurosaka D.
MRI of skeletal muscles in patients with idiopathic inflammatory myopathies: characteristic findings and diagnostic performance in dermatomyositis.
RMD Open. 2019 Mar 28;5(1):e000850.
https://www.ncbi.nlm.nih.gov/pubmed/30997152
- Rosina S, Consolaro A, van Dijkhuizen P, Pistorio A, Varnier GC, Bovis F, Nistala K, Maillard S, Civino A, Tsitsami E, de Inocencio J, Jelusic M, Vojinovic J, Espada G, Makay B, Katsicas MM, Pratsidou-Gertsi P, Lazarevic D, Rao AP, Pires Marafon D, Martini A, Pilkington C, Ruperto N, Ravelli A.
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis.
Rheumatology (Oxford). 2019 Jan 23. doi: 10.1093/rheumatology/key421. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/30690571
- Wienke J, Deakin CT, Wedderburn LR, van Wijk F, van Royen-Kerkhof A.
Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools.
Front Immunol. 2018 Dec 18;9:2951. doi: 10.3389/fimmu.2018.02951.
https://www.ncbi.nlm.nih.gov/pubmed/30619311 - Orandi AB, Dharnidharka VR, Al-Hammadi N, Baszis KW; CARRA Legacy Registry Investigators.
Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis.
Pediatr Rheumatol Online J. 2018 Dec 29;16(1):84. doi: 10.1186/s12969-018-0299-9.
https://www.ncbi.nlm.nih.gov/pubmed/30594206 - Moneta GM, Pires Marafon D, Marasco E, Rosina S, Verardo M, Fiorillo C, Minetti C, Bracci-Laudiero L, Ravelli A, De Benedetti F, Nicolai R.
Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histological Features.
Arthritis Rheumatol. 2018 Dec 15. doi: 10.1002/art.40800. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/30552836
- Yasin SA, Schutz PW, Deakin CT, Sag E, Varsani H, Simou S, Marshall LR, Tansley SL, McHugh NJ, Holton JL, Wedderburn LR, Jacques TS; UK Juvenile Dermatomyositis Research Group (UK-Ireland).
Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features
Neuropathol Appl Neurobiol. 2018 Oct 31. doi: 10.1111/nan.12528. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/30378704 - Huber AM.
Update on the clinical management of juvenile dermatomyositis.
Expert Rev Clin Immunol. 2018 Oct 11:1-8. doi: 10.1080/1744666X.2018.1535901. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/30308133
- Faguer S, Belliere J, Ribes D.
Complement C5-blocking Agent in Refractory Dermatomyositis.
J Rheumatol. 2018 Sep 15. pii: jrheum.180060. doi: 10.3899/jrheum.180060. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/30219762 - Kubínová K, Dejthevaporn R, Mann H, Machado PM, Vencovský J.
The role of imaging in evaluating patients with idiopathic inflammatory myopathies.
Clin Exp Rheumatol. 2018 Sep-Oct;36 Suppl 114(5):74-81.
https://www.ncbi.nlm.nih.gov/pubmed/30296982 - Thyoka M, Adekunle O, Pilkington C, Walters S, Arthurs OJ, Humphries P, Johnson K, Kraft J, Landes C, Persaud T, Sinha R, Offiah AC.
Introduction of a novel magnetic resonance imaging-based scoring system for assessing disease activity in children with juvenile dermatomyositis.
Rheumatology (Oxford). 2018 Sep 1;57(9):1661-1668
https://www.ncbi.nlm.nih.gov/pubmed/29901756 - Mecoli CA, Park JK, Alexanderson H, Regardt M, Needham M, de Groot I, Sarver C, Lundberg IE, Shea B, de Visser M, Song YW, Bingham CO 3rd, Christopher-Stine L.
Perceptions of Patients, Caregivers, and Healthcare Providers of Idiopathic Inflammatory Myopathies: An International OMERACT Study.
J Rheumatol. 2018 Sep 15. pii: jrheum.180353. doi: 10.3899/jrheum.180353. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/30219767 - Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, Meyer A, Tohmé A, Charuel JL, Musset L, Allenbach Y, Benveniste O.
Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.
JAMA Neurol. 2018 Sep 10. doi: 10.1001/jamaneurol.2018.2598. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/30208379 - Vuillard C, Pineton de Chambrun M, de Prost N, Guérin C, Schmidt M, Dargent A, Quenot JP, Préau S, Ledoux G, Neuville M, Voiriot G, Fartoukh M, Coudroy R, Dumas G, Maury E, Terzi N, Tandjaoui-Lambiotte Y, Schneider F, Grall M, Guérot E, Larcher R, Ricome S, Le Mao R, Colin G, Guitton C, Zafrani L, Morawiec E, Dubert M, Pajot O, Mentec H, Plantefève G, Contou D.
Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study.
Ann Intensive Care. 2018 Sep 11;8(1):87
https://www.ncbi.nlm.nih.gov/pubmed/30203297
- van Dijkhuizen EHP, De Iorio M, Wedderburn LR, Deakin CT; JDRG.
Clinical signs and symptoms in a joint model of four disease activity parameters in juvenile dermatomyositis: a prospective, longitudinal, multicenter cohort study.
Arthritis Res Ther. 2018 Aug 15;20(1):180. doi: 10.1186/s13075-018-1687-8.
https://www.ncbi.nlm.nih.gov/pubmed/30111380 - Huber AM.
Juvenile Idiopathic Inflammatory Myopathies.
Pediatr Clin North Am. 2018 Aug;65(4):739-756. doi: 10.1016/j.pcl.2018.04.006.
https://www.ncbi.nlm.nih.gov/pubmed/30031496 - Varnier GC, Pilkington CA, Wedderburn LR.
Juvenile dermatomyositis: novel treatment approaches and outcomes.
Curr Opin Rheumatol. 2018 Aug 16. doi: 10.1097/BOR.0000000000000538. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/30124602 - Sakurai N, Hino-Shishikura A, Nozawa T, Kamide H, Ohara A, Nishimura K, Kikuchi M, Hara R, Mori M, Ito S.
Clinical significance of subcutaneous fat and fascial involvement in juvenile dermatomyositis.
Mod Rheumatol. 2018 Aug 10:1-16. doi: 10.1080/14397595.2018.1511026. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/30092673 - Liphaus BL, Sallum AEM, Aikawa NE, Kiss MHB, Carrasco S, Palmeira P, Lima L, Silva CA, Goldenstein-Schainberg C, Carneiro-Sampaio M.
Increased Soluble Cytoplasmic Bcl-2 Protein Serum Levels and Expression and Decreased Fas Expression in Lymphocytes and Monocytes in Juvenile Dermatomyositis.
J Rheumatol. 2018 Aug 1. pii: jrheum.171248. doi: 10.3899/jrheum.171248. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/30068766
- Mamyrova G, Kishi T, Targoff IN, Ehrlich A, Curiel RV, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.
Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis.
Rheumatology (Oxford). 2018 Jul 16. doi: 10.1093/rheumatology/key190. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/30016492
- Barth Z, Schwartz T, Flatø B, Aaløkken TM, Koller A, Lund MB, Sjaastad I, Sanner H.
The Association Between Nailfold Capillary Density and Pulmonary and Cardiac Involvement in Medium- to Long-standing Juvenile Dermatomyositis.
Arthritis Care Res (Hoboken). 2018 Jun 28. doi: 10.1002/acr.23687
https://www.ncbi.nlm.nih.gov/pubmed/29953739 - Jindal AK, Guleria S, Pilania RK, Bishnoi A, Vinay K, Dogra S, Suri D, Rawat A, Singh S.
Inverse Gottron papules in juvenile dermatomyositis: an under recognized clinical entity.
Rheumatol Int. 2018 Jun;38(6):1153-1160. doi: 10.1007/s00296-018-4038-9
https://www.ncbi.nlm.nih.gov/pubmed/29721695
- Deakin CT, Campanilho-Marques R, Simou S, Moraitis E, Wedderburn LR, Pullenayegum E, Pilkington CA; Juvenile Dermatomyositis Research Group.
Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling.
Arthritis Rheumatol. 2018 May;70(5):785-793. doi: 10.1002/art.40418.
https://www.ncbi.nlm.nih.gov/pubmed/29342499 - Rider LG, Aggarwal R, Machado PM, Hogrel JY, Reed AM, Christopher-Stine L, Ruperto N.
Update on outcome assessment in myositis.
Nat Rev Rheumatol. 2018 May;14(5):303-318. doi: 10.1038/nrrheum.2018.33. Epub 2018 Apr 12.
https://www.ncbi.nlm.nih.gov/pubmed/29651119 - Barth Z, Witczak BN, Flatø B, Koller A, Sjaastad I, Sanner H.
Assessment of Microvascular Abnormalities by Nailfold Capillaroscopy in Juvenile Dermatomyositis After Medium- to Long-Term Followup.
Arthritis Care Res (Hoboken). 2018 May;70(5):768-776. doi: 10.1002/acr.23338. Epub 2018 Mar 23.
https://www.ncbi.nlm.nih.gov/pubmed/28805016 - Aouizerate J, De Antonio M, Bader-Meunier B, Barnerias C, Bodemer C, Isapof A, Quartier P, Melki I, Charuel JL, Bassez G, Desguerre I, Gherardi RK, Authier FJ, Gitiaux C.
Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis.
Rheumatology (Oxford). 2018 May 1;57(5):873-879. doi: 10.1093/rheumatology/kex516.
https://www.ncbi.nlm.nih.gov/pubmed/29474663
- Keller S, Golsari A, Yamamura J.
Juvenile Dermatomyositis.
Rofo. 2018 Apr 26. doi: 10.1055/a-0591-5552. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/29698985 - Tory HO, Carrasco R, Griffin T, Huber AM, Kahn P, Robinson AB, Zurakowski D, Kim S; CARRA Juvenile Dermatomyositis Quality Measures Workgroup.
Comparing the importance of quality measurement themes in juvenile idiopathic inflammatory myositis between patients and families and healthcare professionals.
Pediatr Rheumatol Online J. 2018 Apr 19;16(1):28. doi: 10.1186/s12969-018-0248-7.
https://www.ncbi.nlm.nih.gov/pubmed/29673367 - Rosina S, Varnier GC, Mazzoni M, Lanni S, Malattia C, Ravelli A.
Innovative Research Design to Meet the Challenges of Clinical Trials for JuvenileDermatomyositis.
Curr Rheumatol Rep. 2018 Apr 10;20(5):29. doi: 10.1007/s11926-018-0734-4.
https://www.ncbi.nlm.nih.gov/pubmed/29637406 - Ueki M, Kobayashi I, Takezaki S, Tozawa Y, Okura Y, Yamada M, Kuwana M, Ariga T.
Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies.
Mod Rheumatol. 2018 Apr 9:1-6. doi: 10.1080/14397595.2018.1452353. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/29532710 - Aouizerate J, De Antonio M, Bader-Meunier B, Barnerias C, Bodemer C, Isapof A, Quartier P, Melki I, Charuel JL, Bassez G, Desguerre I, Gherardi RK, Authier FJ, Gitiaux C.
Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juveniledermatomyositis.
Rheumatology (Oxford). 2018 May 1;57(5):873-879. doi:10.1093/rheumatology/kex516.
https://www.ncbi.nlm.nih.gov/pubmed/29474663 - Karasawa R, Tamaki M, Sato T, Tanaka M, Nawa M, Yudoh K, Jarvis JN.
Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics.
Rheumatology (Oxford). 2018 Apr 1;57(4):671-676. doi: 10.1093/rheumatology/kex468.
https://www.ncbi.nlm.nih.gov/pubmed/29361142 - Rider LG, Aggarwal R, Machado PM, Hogrel JY, Reed AM, Christopher-Stine L, Ruperto N.
Update on outcome assessment in myositis.
Nat Rev Rheumatol. 2018 May;14(5):303-318. doi: 10.1038/nrrheum.2018.33. Epub 2018 Apr 12.
https://www.ncbi.nlm.nih.gov/pubmed/29651119
- Ueki M, Kobayashi I, Takezaki S, Tozawa Y, Okura Y, Yamada M, Kuwana M, Ariga T.
Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies.
Mod Rheumatol. 2018 Mar 13:1-16.
https://www.ncbi.nlm.nih.gov/pubmed/29532710 - Santos-Briz A, Calle A, Linos K, Semans B, Carlson A, Sangüeza OP, Metze D, Cerroni L, Díaz-Recuero JL, Alegría-Landa V, Mascaró JM, Moreno C, Rodríguez-Peralto JL, Requena L.
Dermatomyositis panniculitis: a clinicopathological and immunohistochemical study of 18 cases.
J Eur Acad Dermatol Venereol. 2018 Mar 10. doi: 10.1111/jdv.14932. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/29524269
- Miyamae T, Hara T, Hanaya A, Tani Y, Kishi T, Yamanaka H.
Effect of Adalimumab on Refractory Arthritis in Juvenile Idiopathic Inflammatory Myopathy with Anti-MDA5 Autoantibody.
Case Rep Rheumatol. 2018 Feb 6;2018:2164312. doi: 10.1155/2018/2164312. eCollection 2018.
https://www.ncbi.nlm.nih.gov/pubmed/29552370
- Yeker RM, Pinal-Fernandez I, Kishi T, Pak K, Targoff IN, Miller FW, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group.
Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenilemyositis.
Ann Rheum Dis. 2018 Jan 23. pii: annrheumdis-2017-212436. doi: 10.1136/annrheumdis-2017-212436. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/29363513 - Deakin CT, Campanilho-Marques R, Simou S, Moraitis E, Wedderburn LR, Pullenayegum E, Pilkington CA; Juvenile Dermatomyositis Research Group (JDRG).
Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modelling.
Arthritis Rheumatol. 2018 Jan 17. doi: 10.1002/art.40418. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/29342499 - Silverberg JI, Kwa L, Kwa MC, Laumann AE, Ardalan K.
Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample.
Rheumatology (Oxford). 2018 Jan 24. doi: 10.1093/rheumatology/kex465. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/29373707 - Karasawa R, Tamaki M, Sato T, Tanaka M, Nawa M, Yudoh K, Jarvis JN.
Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics.
Rheumatology (Oxford). 2018 Jan 18. doi: 10.1093/rheumatology/kex468. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/29361142
- Lundberg IE, Tjärnlund A, Bottai M The International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland), et al.
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
Ann Rheum Dis. 2017 Dec;76(12):1955-1964.
https://www.ncbi.nlm.nih.gov/pubmed/29106061 - Varnier GC, Rosina S, Ferrari C, Pistorio A, Consolaro A, Bovis F, Dalprà S, Pilkington C, Maillard S, Civino A, Tsitsami E, de Inocencio J, Jelusic M, Vojinovic J, Espada G, Makay B, Katsicas MM, Pratsidou-Gertsi P, Lazarevic D, Rao AP, Pires Marafon D, Ruperto N, Martini A, Ravelli A.
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care.
Arthritis Care Res (Hoboken). 2017 Dec 15. doi: 10.1002/acr.23491. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/29245175
- Schmidt K, Schmidt J.
Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment.
Curr Opin Rheumatol. 2017 Nov;29(6):632-638
https://www.ncbi.nlm.nih.gov/pubmed/28832349 - Diederichsen LP.
Cardiovascular involvement in myositis.
Curr Opin Rheumatol. 2017 Nov;29(6):598-603
https://www.ncbi.nlm.nih.gov/pubmed/28841590 - Tansley SL, Simou S, Shaddick G, Betteridge ZE, Almeida B, Gunawardena H, Thomson W, Beresford MW, Midgley A, Muntoni F, Wedderburn LR, McHugh NJ.
Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort.
J Autoimmun. 2017 Nov;84:55-64
https://www.ncbi.nlm.nih.gov/pubmed/28663002 - Challa D, Crowson CS, Niewold TB, Reed AM; CARRA Legacy Registry Investigators.
Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry.
Clin Rheumatol. 2017 Nov 23.
https://www.ncbi.nlm.nih.gov/pubmed/29170979 - Bottai M, Tjärnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, García-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinka M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Wook Song Y, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, Lundberg IE; International Myositis Classification Criteria Project consortium, the Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland).
EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report.
RMD Open. 2017 Nov 14;3(2):e000507
https://www.ncbi.nlm.nih.gov/pubmed/29177080
- Tjärnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Tomasová Studýnková J, Chura R, Gullick NJ, Salerno R, Rönnelid J, Alexanderson H, Lindroos E, Aggarwal R, Gordon P, Vencovsky J, Lundberg IE.
Abatacept in the treatment of adult dermatomyositis and polymyositis: A randomised, phase IIb treatment delayed-start trial.
Ann Rheum Dis. 2017 Oct 9. pii: annrheumdis-2017-211751. doi: 10.1136/annrheumdis-2017-211751. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/28993346 - McCann LJ, Pilkington CA, Huber AM, Ravelli A, Appelbe D, Kirkham JJ, Williamson PR, Aggarwal A, Christopher-Stine L, Constantin T, Feldman BM, Lundberg I, Maillard S, Mathiesen P, Murphy R, Pachman LM, Reed AM, Rider LG, van Royen-Kerkof A, Russo R, Spinty S, Wedderburn LR, Beresford MW.
Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research
Ann Rheum Dis. 2017 Oct 30. pii: annrheumdis-2017-212141. doi: 10.1136/annrheumdis-2017-212141. [Epub ahead of print]
https://www-ncbi-nlm-nih-gov.sire.ub.edu/pubmed/29084729 - Li J, Liu Y, Li Y, Li F, Wang K, Pan W, Meng D.
Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: A systematic meta-analysis.
J Dermatol. 2017 Oct 6. doi: 10.1111/1346-8138.14092. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/28983955 - Besançon A, Brochard K, Dupic L, Gitiaux C, Delville M, Krid S, Quartier P, Saire E, Salomon R, Talbotec C, Bodemer C, Bader-Meunier B.
Presentations and outcomes of juvenile dermatomyositis patients admitted to intensive care units.
Rheumatology (Oxford). 2017 Oct 1;56(10):1814-1816. doi: 10.1093/rheumatology/kex267.
https://www.ncbi.nlm.nih.gov/pubmed/28957568 - Meneghel A, Martini G, Birolo C, Tosoni A, Pettenazzo A, Zulian F.
Life-threatening systemic capillary leak syndrome in juvenile dermatomyositis.
Rheumatology (Oxford). 2017 Oct 1;56(10):1822-1823. doi: 10.1093/rheumatology/kex262.
https://www.ncbi.nlm.nih.gov/pubmed/28957546 - McCann LJ, Pilkington CA, Huber AM, Ravelli A, Appelbe D, Kirkham JJ, Williamson PR, Aggarwal A, Christopher-Stine L, Constantin T, Feldman BM, Lundberg I, Maillard S, Mathiesen P, Murphy R, Pachman LM, Reed AM, Rider LG, van Royen-Kerkof A, Russo R, Spinty S, Wedderburn LR, Beresford MW.
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
Ann Rheum Dis. 2017 Oct 30. pii: annrheumdis-2017-212141. doi: 10.1136/annrheumdis-2017-212141. [Epub ahead of print]
https://www-ncbi-nlm-nih-gov.sire.ub.edu/pubmed/29079590
- Orandi AB, Baszis KW, Dharnidharka VR, Huber AM, Hoeltzel MF; CARRA Juvenile Myositis subgroup.
Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA).
Pediatr Rheumatol Online J. 2017 Sep 21;15(1):71. doi: 10.1186/s12969-017-0199-4.
https://www.ncbi.nlm.nih.gov/pubmed/28934971 - Nuño-Nuño L, Joven BE, Carreira PE, Maldonado-Romero V, Larena-Grijalba C, Cubas IL, Tomero EG, Barbadillo-Mateos MC, De la Peña Lefebvre PG, Ruiz-Gutiérrez L, López-Robledillo JC, Moruno-Cruz H, Pérez A, Cobo-Ibáñez T, Almodóvar González R, Lojo L, García De Yébenes MJ, López-Longo FJ.
Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain.
Rheumatol Int. 2017 Sep 2. doi: 10.1007/s00296-017-3799-x. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28866745 - Sharma N, Putman MS, Vij R, Strek ME, Dua A.
Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort.
J Rheumatol. 2017 Sep 1. pii: jrheum.161217. doi: 10.3899/jrheum.161217. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/28864644
- Barth Z, Witczak BN, Flatø B, Koller A, Sjaastad I, Sanner H.
Microvascular Abnormalities Assessed by Nailfold Capillaroscopy In Juvenile Dermatomyositis After Medium to Long-Term Follow-Up.
Arthritis Care Res (Hoboken). 2017 Aug 13. doi: 10.1002/acr.23338. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/28805016 - Rider LG, Ruperto N, Pistorio A, Erman B, Bayat N, Lachenbruch PA, et al for the International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects.
Rheumatology (Oxford). 2017 Aug 2. doi: 10.1093/rheumatology/kex226. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/28977549
- Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham B, Weiss PF, Horkayne-Szakaly I, Targoff IN, Miller FW, Mammen AL; Childhood Myositis Heterogeneity Study Group.
Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients
.Arthritis Care Res (Hoboken). 2017 Jul;69(7):1088-1094. doi: 10.1002/acr.23113.
https://www.ncbi.nlm.nih.gov/pubmed/28129483 - Mamyrova G, Rider LG, Ehrlich A, Jones O, Pachman LM, Nickeson R, Criscone-Schreiber LG, Jung LK, Miller FW, Katz JD.
Environmental factors associated with disease flare in juvenile and adult dermatomyositis
Rheumatology, Volume 56, Issue 8, 1 August 2017, Pages 1342–1347
https://www.ncbi.nlm.nih.gov/pubmed/28444299 - Cantez S, Gross GJ, MacLusky I, Feldman BM.
Cardiac findings in children with juvenile Dermatomyositis at disease presentation.
Pediatr Rheumatol Online J. 2017 Jul 11;15(1):54. doi: 10.1186/s12969-017-0182-0.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504613/ - Spencer CH, Rouster-Stevens K, Gewanter H, Syverson G, Modica R, Schmidt K, Emery H, Wallace C, Grevich S, Nanda K, Zhao YD, Shenoi S, Tarvin S, Hong S, Lindsley C0, Weiss JE, Passo M, Ede K, Brown A, Ardalan K, Bernal W, Stoll ML, Lang B, Carrasco R, Agaiar C, Feller L, Bukulmez H, Vehe R, Kim H, Schmeling H, Gerstbacher D, Hoeltzel M, Eberhard B, Sundel R, Kim S, Huber AM, Patwardhan A; Pediatric Rheumatologist Collaborators.
Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
Pediatr Rheumatol Online J. 2017 Jun 13;15(1):50. doi: 10.1186/s12969-017-0174-0.
https://www.ncbi.nlm.nih.gov/pubmed/28610606
- Spencer CH, Rouster-Stevens K, Gewanter H, Syverson G, Modica R, Schmidt K, Emery H, Wallace C, Grevich S, Nanda K, Zhao YD, Shenoi S, Tarvin S, Hong S, Lindsley C, Weiss JE, Passo M, Ede K, Brown A, Ardalan K, Bernal W, Stoll ML, Lang B, Carrasco R, Agaiar C, Feller L, Bukulmez H, Vehe R, Kim H, Schmeling H, Gerstbacher D, Hoeltzel M, Eberhard B, Sundel R, Kim S, Huber AM, Patwardhan A; Pediatric Rheumatologist Collaborators.
Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
Pediatr Rheumatol Online J. 2017 Jun 13;15(1):50.
https://www.ncbi.nlm.nih.gov/pubmed/28610606 - Berntsen KS, Tollisen A, Schwartz T, Kirkhus E, Aaløkken TM, Lund MB, Flatø B, Sjaastad I, Sanner H.
Submaximal Exercise Capacity in Juvenile Dermatomyositis after Longterm Disease: The Contribution of Muscle, Lung, and Heart Involvement.
J Rheumatol. 2017 Jun;44(6):827-834.
https://www.ncbi.nlm.nih.gov/pubmed/28365577
- Phillippi K, Hoeltzel M, Byun Robinson A, Kim S; Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry Investigators
Race, Income, and Disease Outcomes in Juvenile Dermatomyositis.
J Pediatr. 2017 Mar 3. pii: S0022-3476(17)30156-7. doi: 10.1016/j.jpeds.2017.01.046. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/28410093 - Tiao J, Feng R, Berger EM, Brandsema JF, Coughlin CC, Khan N, Kichula EA, Lerman MA, Lvovich S, McMahon PJ, Rider LG, Rubin AI, Scalzi LV, Smith DM, Taxter AJ, Treat JR, Williams RP, Yum SW, Okawa J, Werth VP.
Evaluation of the Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and the Cutaneous Assessment Tool Binary Method (CAT-BM) in Juvenile Dermatomyositis Among Pediatric Dermatologists, Rheumatologists, and Neurologists
Br J Dermatol. 2017 Apr 19. doi: 10.1111/bjd.15596. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/28421601
- Loaiza-Félix J, Moreno-Ramírez M, Pérez-García FL, Jiménez-Rojas V, Sánchez-Muñoz F, Amezcua-Guerra ML.
Serum levels of adipokines in patients with idiopathic inflammatory myopathies: a pilot study.
Rheumatol Int. 2017 May 23. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/?term=28536758 - Hussain A, Rawat A, Jindal AK, Gupta A, Singh S.
Autoantibodies in children with juvenile dermatomyositis: A single centre experience from North-West India.
Rheumatol Int. 2017 May;37(5):807-812. doi: 10.1007/s00296-017-3707-4.
https://www.ncbi.nlm.nih.gov/pubmed/?term=28331982 - Hashkes PJ.
Race and income affects outcomes in juvenile dermatomyositis.
J Pediatr. 2017 May;184:2. doi: 10.1016/j.jpeds.2017.03.012.
https://www.ncbi.nlm.nih.gov/pubmed/?term=28434566 - Phillippi K, Hoeltzel M, Byun Robinson A, Kim S; Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry Investigators.
Race, Income, and Disease Outcomes in Juvenile Dermatomyositis.
J Pediatr. 2017 May;184:38-44.e1. doi: 10.1016/j.jpeds.2017.01.046.
https://www.ncbi.nlm.nih.gov/pubmed/?term=28410093
- Phillippi K, Hoeltzel M, Byun Robinson A, Kim S; Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry Investigators
Race, Income, and Disease Outcomes in Juvenile Dermatomyositis.
J Pediatr. 2017 Mar 3. pii: S0022-3476(17)30156-7. doi: 10.1016/j.jpeds.2017.01.046. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/28410093 - Tiao J, Feng R, Berger EM, Brandsema JF, Coughlin CC, Khan N, Kichula EA, Lerman MA, Lvovich S, McMahon PJ, Rider LG, Rubin AI, Scalzi LV, Smith DM, Taxter AJ, Treat JR, Williams RP, Yum SW, Okawa J, Werth VP.
Evaluation of the Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and the Cutaneous Assessment Tool Binary Method (CAT-BM) in Juvenile Dermatomyositis Among Pediatric Dermatologists, Rheumatologists, and Neurologists
Br J Dermatol. 2017 Apr 19. doi: 10.1111/bjd.15596. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/28421601
- Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Magalhaes CS, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, Ruperto N; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
Arthritis Rheumatol. 2017 Apr 6. doi: 10.1002/art.40060. [Epub ahead of print].
https://www.ncbi.nlm.nih.gov/pubmed/28382778 - Berntsen KS, Tollisen A, Schwartz T, Kirkhus E, Aaløkken TM, Lund MB, Flatø B, Sjaastad I, Sanner H.
Submaximal Exercise Capacity in Juvenile Dermatomyositis after Longterm Disease: The Contribution of Muscle, Lung, and Heart Involvement.
J Rheumatol. 2017 Apr 1. pii: jrheum.160997. doi: 10.3899/jrheum.160997. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/28365577 - Wang CR.
Successful Treatment of Refractory Juvenile Dermatomyositis With Adalimumab.
J Clin Rheumatol. 2017 Apr;23(3):174-175. doi: 10.1097/RHU.0000000000000514.
https://www.ncbi.nlm.nih.gov/pubmed/28333871
- Tansley SL, Betteridge ZE, Simou S, Jacques TS, Pilkington C, Wood M, Warrier K, Wedderburn LR, McHugh NJ; Juvenile Dermatomyositis Research Group.
Anti-HMGCR Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies Identify a Rare but Clinically Important Subset of Patients.
J Rheumatol. 2017 Feb 15. pii: jrheum.160871. doi: 10.3899/jrheum.160871. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/28202739 - Montoya CL, Gonzalez ML, Ospina FE, Tobón GJ.
A Rare Case of Amyopathic Juvenile Dermatomyositis Associated With Psoriasis Successfully Treated With Ustekinumab.
J Clin Rheumatol. 2017 Mar;23(2):129-130. doi: 10.1097/RHU.0000000000000430.
https://www.ncbi.nlm.nih.gov/pubmed/28099216 - McCann LJ, Pain CE.
A Practical Approach to Juvenile Dermatomyositis and Juvenile Scleroderma.
Indian J Pediatr. 2016 Feb;83(2):163-71.
https://www.ncbi.nlm.nih.gov/pubmed/26489640
- Aggarwal R, Loganathan P, Koontz D2, Qi Z, Reed AM, Oddis CV
Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab.
Rheumatology (Oxford). 2017 Feb;56(2):247-254. doi: 10.1093/rheumatology/kew396. Epub 2016 Nov 11.
https://www.ncbi.nlm.nih.gov/pubmed/27837048 - Liang WC, Uruha A, Suzuki S, Murakami N, Takeshita E, Chen WZ, Jong YJ, Endo Y3, Komaki H, Fujii T, Kawano Y, Mori-Yoshimura M, Oya Y, Xi J, Zhu W, Zhao C, Watanabe Y, Ikemoto K, Nishikawa A, Hamanaka K, Mitsuhashi S, Suzuki N, Nishino I
Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies.
Rheumatology (Oxford). 2017 Feb;56(2):287-293. doi: 10.1093/rheumatology/kew386. Epub 2016 Nov 6.
https://www.ncbi.nlm.nih.gov/pubmed/27818386 - Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham B, Weiss PF, Horkayne-Szakaly I, Targoff IN, Miller FW, Mammen AL; Childhood Myositis Heterogeneity Study Group.
Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies are Associated with DRB1*07:01 and Severe Myositis in Pediatric Myositis Patients.
Arthritis Care Res (Hoboken). 2017 Jan 27. doi: 10.1002/acr.23113. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/28129483 - Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, Lahdenne P, Magnusson B, Nistala K, Ozen S, Pilkington C, Ravelli A, Russo R, Uziel Y, van Brussel M, van der Net J, Vastert S, Wedderburn LR, Wulffraat N, McCann LJ, van Royen-Kerkhof A.
Consensus-based recommendations for the management of juvenile dermatomyositis.
Ann Rheum Dis. 2017 Feb;76(2):329-340. doi: 10.1136/annrheumdis-2016-209247. Epub 2016 Aug 11.
https://www.ncbi.nlm.nih.gov/pubmed/27515057
- Ibarra M, Rigsby C, Morgan GA, Sammet CL, Huang CC, Xu D, Targoff IN, Pachman LM.
Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography.
Pediatr Rheumatol Online J. 2016 Nov 29;14(1):64.
https://www.ncbi.nlm.nih.gov/pubmed/27894310 - Huber AM, Kim S, Reed AM, Carrasco R, Feldman BM, Hong SD, Kahn P, Rahimi H, Robinson AB, Vehe RK, Weiss JE, Spencer C; and the Juvenile Dermatomyositis Research Committee of the Childhood Arthritis and Rheumatology Research Alliance.
Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash.
J Rheumatol. 2016 Nov 1.
https://www.ncbi.nlm.nih.gov/pubmed/27803135 - López De Padilla CM, Crowson CS, Hein MS, Pendegraft RS, Strausbauch MA, Niewold TB, Ernste FC, Peterson E, Baechler EC, Reed AM.
Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis.
J Rheumatol. 2016 Nov 1.
https://www.ncbi.nlm.nih.gov/pubmed/27803134
- Deakin CT, Yasin SA, Simou S, Arnold KA, Tansley SL, Betteridge ZE, McHugh NJ, Varsani H, Holton JL, Jacques TS, Pilkington CA, Nistala K, Wedderburn LR; UK Juvenile Dermatomyositis Research Group..
Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis.
Arthritis Rheumatol. 2016 Nov;68(11):2806-2816. doi: 10.1002/art.39753
https://www.ncbi.nlm.nih.gov/pubmed/27214289
- Wakiguchi H, Takei S, Kawano Y.
Axillary Skin Ulcers in Infants with Juvenile Dermatomyositis.
Pediatr Neonatol. 2016 Sep 20.
https://www.ncbi.nlm.nih.gov/pubmed/27733312 - Razmi T M, Vinay K, Parsad D.
Trachyonychia in juvenile dermatomyositis: nail as a mirror to disease activity.
Rheumatology (Oxford). 2016 Sep 27.
https://www.ncbi.nlm.nih.gov/pubmed/27677537 - Owen ED, Choy EH, Piguet V.
Juvenile dermatomyositis: new clinical trial evidence to underpin therapeutic shared decision making.
Br J Dermatol. 2016 Oct;175(4):665-6. doi: 10.1111/bjd.14917.
https://www.ncbi.nlm.nih.gov/pubmed/27650736
- Tansley SL.
Antibodies in juvenile-onset myositis.
Curr Opin Rheumatol. 2016 Nov;28(6):645-650.
http://www.ncbi.nlm.nih.gov/pubmed/27533322 - Speth F, Haas JP, Hinze CH.
Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases.
Pediatr Rheumatol Online J. 2016 Sep 13;14(1):52.
http://www.ncbi.nlm.nih.gov/pubmed/27623619 - Paik JJ, Christopher-Stine L.
A case of refractory dermatomyositis responsive to tofacitinib
Semin Arthritis Rheum 2016 Epub
http://www.semarthritisrheumatism.com/article/S0049-0172(16)30200-1/abstract - Fotis L, Baszis KW, White AJ, French AR.
Four Cases of Anti-PM/Scl Antibody-positive Juvenile Overlap Syndrome with Features of Myositis and Systemic Sclerosis.
J Rheumatol. 2016 Sep;43(9):1768-9.
http://www.ncbi.nlm.nih.gov/pubmed/27587018 - Li T, Guo L, Chen Z, Gu L, Sun F, Tan X, Chen S, Wang X, Ye S.
Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis.
Sci Rep. 2016 Sep 12;6:33226.
http://www.ncbi.nlm.nih.gov/pubmed/27615411 - Sato S, Uejima Y, Nanbu M, Suganuma E, Takano T, Tanaka R, Kabuki T, Oguma E, Oh-Ishi T, Kawano Y.
Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis.
Mod Rheumatol. 2016 Sep 20:1-5. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/27588444
- Leverenz D, Zaha O, Crofford LJ, Chung CP.
Causes of creatine kinase levels greater than 1000 IU/L in patients referred to rheumatology.
Clin Rheumatol. 2016 Jun;35(6):1541-7. doi: 10.1007/s10067-016-3242-9.
http://www.ncbi.nlm.nih.gov/pubmed/27041384
- Preuße C, Allenbach Y, Hoffmann O, Goebel HH, Pehl D, Radke J, Doeser A, Schneider U, Alten RH, Kallinich T, Benveniste O, von Moers A, Schoser B, Schara U, Stenzel W.
Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis.
Acta Neuropathol Commun. 2016 Apr 27;4(1):45. doi: 10.1186/s40478-016-0308-5.
http://www-ncbi-nlm-nih-gov.sire.ub.edu/pubmed/27121733 - Pinto AJ, Yazigi Solis M, de Sá Pinto AL, Silva CA, Maluf Elias Sallum A, Roschel H, Gualano B.
Physical (in)activity and its influence on disease-related features, physical capacity, and health-related quality of life in a cohort of chronic juvenile dermatomyositis patients.
Semin Arthritis Rheum. 2016 Mar 18. pii: S0049-0172(16)00102-5. doi: 10.1016/j.semarthrit.2016.03.010.
http://www-ncbi-nlm-nih-gov.sire.ub.edu/pubmed/27113390
- Rider LG, Nistala K.
The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes.
J Intern Med. 2016 Mar 30. doi: 10.1111/joim.12444. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/27028907 - de Inocencio J, Enríquez-Merayo E, Casado R, González-Granado LI.
Subcutaneous Immunoglobulin in Refractory Juvenile Dermatomyositis.
Pediatrics. 2016 Mar 10. pii: peds.2015-3537. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26966131 - Salman A, Kasapcopur O, Ergun T, Durmus Ucar AN, Demirkesen C.
Panniculitis in juvenile dermatomyositis: Report of a case and review of the published work.
J Dermatol. 2016 Mar 12. doi: 10.1111/1346-8138.13335. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26971888 - Saini I, Kalaivani M, Kabra SK.
Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome.
Rheumatol Int. 2016 Mar 23. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/27007612 - Habers GE, Bos GJ, van Royen-Kerkhof A, Lelieveld OT, Armbrust W, Takken T, van Brussel M.
Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis.
Rheumatology (Oxford). 2016 Mar 27. pii: kew026. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/27018060 - Pinto AJ, Roschel H, Benatti FB, de Sá Pinto AL, Sallum AM, Silva CA, Gualano B.
Poor agreement of objectively measured and self-reported physical activity in juvenile dermatomyositis and juvenile systemic lupus erythematosus.
Clin Rheumatol. 2016 Mar 28. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/27021334
- Campanilho-Marques R, Almeida B, Deakin C, Arnold K, Gallot N, de Iorio M, Nistala K, Pilkington CA, Wedderburn LR; Juvenile Dermatomyositis Research Group (JDRG).
Comparison of the utility and validity of three scoring tools to measure skin involvement in patients with Juvenile Dermatomyositis.
Arthritis Care Res (Hoboken). 2016 Feb 16. doi: 10.1002/acr.22867. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26881696 - Alexanderson H.
Physical exercise as a treatment for adult and juvenile myositis.
J Intern Med. 2016 Feb 8. doi: 10.1111/joim.12481. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26854121 - Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, Fischbach M, Magnusson B, Sterba G, Avcin T, Brochard K, Corona F, Dressler F, Gerloni V, Apaz MT, Bracaglia C, Cespedes-Cruz A, Cimaz R, Couillault G, Joos R, Quartier P, Russo R, Tardieu M, Wulffraat N,Bica B, Dolezalova P, Ferriani V, Flato B, Bernard-Medina AG, Herlin T, Trachana M, Meini A, Allain-Launay E, Pilkington C, Vargova V,Wouters C, Angioloni S, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO).
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial.
Lancet. 2016 Feb 13;387(10019):671-8. doi: 10.1016/S0140-6736(15)01021-1. Epub 2015 Nov 30.
http://www.ncbi.nlm.nih.gov/pubmed/26645190
- G Esther A Habers, Adam M Huber, Gulnara Mamyrova, Ira N Targoff, Terrance P O'Hanlon, Sharon Adams, Janardan P Pandey, Chantal Boonacker, Marco van Brussel, Frederick W Miller, Annet van Royen-Kerkhof, Lisa G Rider and Childhood Myositis Heterogeneity Study Group
Myositis autoantibodies, clinical features, and environmental exposures at illness onset are associated with disease course in juvenile myositis
Arthritis & Rheumatology DOI: 10.1002/art.39466
Abstract - Tansley, Sarah; Wedderburn, Lucy R.
Comparing and contrasting clinical and serological features of juvenile and adult-onset myositis: implications for pathogenesis and outcomes
Current Opinion in Rheumatology:
November 2015 - Volume 27 - Issue 6 - p 601–607
doi: 10.1097/BOR.0000000000000224 - Hiroyuki Wakiguchi, Shunji Hasegawa, Reiji Hirano, Hidenobu Kaneyasu, Midori Wakabayashi-Takahara, Shouichi Ohga
Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and -18 levels
Pediatric Rheumatology 2015, 13:49 (18 November 2015)
Abstract
- Habers GE, Huber AM, Mamyrova G, Targoff IN, O'Hanlon TP, Adams S, Pandey JP, Boonacker C, van Brussel M, Miller FW, van Royen-Kerkhof A, Rider LG; Childhood Myositis Heterogeneity Study Group.
Myositis autoantibodies, clinical features, and environmental exposures at illness onset are associated with disease course in juvenile myositis.
Arthritis Rheumatol. 2015 Oct 16. doi: 10.1002/art.39466.
http://www.ncbi.nlm.nih.gov/pubmed/26474155 - Tansley S, Wedderburn LR.
Comparing and contrasting clinical and serological features of juvenile and adult-onset myositis: implications for pathogenesis and outcomes
Curr Opin Rheumatol. 2015 Nov;27(6):601-7. doi: 10.1097/BOR.0000000000000224.
http://www.ncbi.nlm.nih.gov/pubmed/26352731 - Barth Z, Nomeland Witczak B, Schwartz T, Gjesdal K, Flatø B, Koller A, Sanner H, Sjaastad I.
In juvenile dermatomyositis, heart rate variability is reduced, and associated with both cardiac dysfunction and markers of inflammation: a cross-sectional study median 13.5 years after symptom onset.
Rheumatology (Oxford). 2015 Oct 24. pii: kev376. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26500284 - Pagnini I, Vitale A, Selmi C, Cimaz R, Cantarini L.
Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms
Clin Rev Allergy Immunol. 2015 Oct 1. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/26429707
- Miller FW, Chen W, O'Hanlon TP, Cooper RG, Vencovsky J, Rider LG, Danko K, Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, Padyukov L, Selva-O'Callaghan A, Radstake TR, Isenberg DA, Chinoy H, Ollier WE, Scheet P, Peng B, Lee A, Byun J, Lamb JA, Gregersen PK, Amos CI.
Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes.
Genes Immun. 2015 Oct;16(7):470-80. doi: 10.1038/gene.2015.28.
http://www.ncbi.nlm.nih.gov/pubmed/26291516 - Rothwell S, Cooper RG, Lundberg IE, Miller FW, Gregersen PK, Bowes J, Vencovsky J, Danko K, Limaye V, Selva-O'Callaghan A, Hanna MG, Machado PM, Pachman LM, Reed AM, Rider LG, Cobb J, Platt H, Molberg Ø, Benveniste O, Mathiesen P, Radstake T, Doria A, De Bleecker J, De Paepe B, Maurer B, Ollier WE, Padyukov L, O'Hanlon TP, Lee A, Amos CI, Gieger C, Meitinger T, Winkelmann J, Wedderburn LR, Chinoy H, Lamb JA; Myositis Genetics Consortium.
Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups.
Ann Rheum Dis. 2015 Sep 11. pii: annrheumdis-2015-208119. doi: 10.1136/annrheumdis-2015-208119. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26362759
- van Brussel M, van Oorschot JW, Schmitz JP, Nicolay K, van Royen-Kerkhof A, Takken T, Jeneson JA.
Muscle Metabolic Responses During Dynamic In-Magnet Exercise Testing: A Pilot Study in Children with an Idiopathic Inflammatory Myopathy.
Acad Radiol. 2015 Aug 7. doi:10.1016/j.acra.2015.06.013. EPUB
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/26259546 - Cañas CA, Bonilla-Abadía F, Mejía M, Tobón GJ.
Recovery of Severe Muscular and Fascial Calcinosis After Treatment With Bisphosphonates in a Child With Juvenile Dermatomyositis.
J Clin Rheumatol. 2015 Aug;21(5):267-9. doi:10.1097/RHU.0000000000000264.
http://www.ncbi.nlm.nih.gov/pubmed/26203832 - Almeida B, Campanilho-Marques R, Arnold K, Pilkington CA, Wedderburn LR, Nistala K; Juvenile Dermatomyositis Research Group.
Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated.
Arthritis Rheumatol. 2015 Sep;67(9):2495-502. doi:10.1002/art.39200.
http://www.ncbi.nlm.nih.gov/pubmed/25988361
- Lightfoot AP, McArdle A, Jackson MJ, Cooper RG.
In the idiopathic inflammatory myopathies (IIM), do reactive oxygen species (ROS) contribute to muscle weakness?
Ann Rheum Dis. 2015 Jul;74(7):1340-1346. doi: 10.1136/annrheumdis-2014-207172. Review.
http://www.ncbi.nlm.nih.gov/pubmed/26063809 - Iglesias E, Bou R, Torrente-Segarra V, Antón J.
Importancia de un estudio basal completo en pacientes con diagnóstico de dermatomiositis juvenil
An Pediatr (Barc). 2015 Jun;82(6):449-50. doi: 10.1016/j.anpedi.2015.01.011.
http://www.ncbi.nlm.nih.gov/pubmed/25746608
- Norimoto Kobayashi, Shunichiro Takezaki, Ichiro Kobayashi, Naomi Iwata, Masaaki Mori, Kazushige Nagai, Naoko Nakano, Mari Miyoshi, Noriko Kinjo, Takuji Murata, Kenji Masunaga, Hiroaki Umebayashi, Tomoyuki Imagawa, Kazunaga Agematsu, Shinji Sato, Masataka Kuwana, Masafumi Yamada, Shuji Takei, Shumpei Yokota, Kenichi Koike, and Tadashi Ariga
Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis
Rheumatology (2015) 54 (5): 784-791 doi:10.1093/rheumatology/keu385
http://rheumatology.oxfordjournals.org/content/54/5/784.abstract
- Olazagasti JM, Hein M, Crowson CS, de Padilla CL, Peterson E, Baechler EC, Reed AM.
Adipokine gene expression in peripheral blood of adult and juvenile dermatomyositis patients and their relation to clinical parameters and disease activity measures.
J Inflamm (Lond). 2015 Apr 9;12:29. doi: 10.1186/s12950-015-0075-2. eCollection 2015.
http://www.ncbi.nlm.nih.gov/pubmed/25918482
Acceso directo: http://www.journal-inflammation.com/content/pdf/s12950-015-0075-2.pdf
- Tayfur AC, Topaloglu R, Gulhan B, Bilginer Y.
Bisphosphonates in juvenile dermatomyositis with dystrophic calcinosis.
Mod Rheumatol. 2015 Mar 24:1-6. [Epub ahead of print].
http://www.ncbi.nlm.nih.gov/pubmed/25800510 - Smith VM, Leone V, Clark S.
Palmoplantar Hyperkeratosis: A Rare Cutaneous Manifestation of Juvenile Dermatomyositis
Pediatr Dermatol. 2015 Mar 17. doi: 10.1111/pde.12540. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/25782089 - Hozumi H, Enomoto N, Kono M, Fujisawa T, Inui N, Nakamura Y, Sumikawa H, Johkoh T, Nakashima R, Imura Y, Mimori T, Suda T.
Prognostic Significance of Anti-Aminoacyl-tRNA Synthetase Antibodies in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease: A Retrospective Case Control Study.
PLoS One. 2015 Mar 19;10(3):e0120313. doi: 10.1371/journal.pone.0120313. eCollection 2015.
http://www.ncbi.nlm.nih.gov/pubmed/25789468 - Iglesias E, Bou R, Torrente-Segarra V, Antón J.
Importancia de un estudio basal completo en pacientes con diagnóstico de dermatomiositis juvenil
An Pediatr (Barc). 2015 Mar 3. pii: S1695-4033(15)00054-5. doi: 10.1016/j.anpedi.2015.01.011. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/25746608
http://ac.els-cdn.com/S1695403315000545/1-s2.0-S1695403315000545-main.pdf?_tid=eb58946c-d7a2-11e4-83ff-00000aacb35d&acdnat=1427805726_68732f7b698403b95e3035766030a1df
- Otero Rivas MM, Vicente Villa A, González Lara L, Suñol Capella M, Antón López J, González Enseñat MA.
Panniculitis in juvenile dermatomyositis.
Clin Exp Dermatol. 2015 Feb 16.
http://www.ncbi.nlm.nih.gov/pubmed/25682744 - Hung CH.
Treatment and clinical outcome of juvenile dermatomyositis.
Pediatr Neonatol. 2015 Feb;56(1):1-2.
http://www.ncbi.nlm.nih.gov/pubmed/25487198
- Varsani H, Charman SC, Li CK, Marie SK, Amato AA, Banwell B, Bove KE, Corse AM, Emslie-Smith AM, Jacques TS, Lundberg IE, Minetti C, Nennesmo I, Rushing EJ, Sallum AM, Sewry C, Pilkington CA, Holton JL, Wedderburn LR; UK Juvenile Dermatomyositis Research Group.
Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease.
Ann Rheum Dis. 2015 Jan;74(1):204-10. doi: 10.1136/annrheumdis-2013-203396. Epub 2013 Sep 24.
http://www.ncbi.nlm.nih.gov/pubmed/24064003
- Kurasawa K, Arai S.
Optimal management of interstitial lung disease associated with dermatomyositis/polymyositis: lessons from the Japanese experience.
Orphan Drugs Res Rev 2014 Nov;4:93-107. doi http://dx.doi.org/10.2147/ODRR.S50355
http://www.dovepress.com/optimal-management-of-interstitial-lung-disease-associated-with-dermat-peer-reviewed-article-ODRR# - Habers GE, van Brussel M, Bhansing KJ, Hoppenreijs EP, Janssen AJ, van Royen-Kerkhof A, Pillen S.
Quantitative Muscle Ultrasonography in the Follow-Up of Juvenile Dermatomyositis.
Muscle Nerve. 2014 Dec 30. doi: 10.1002/mus.24564.
http://www.ncbi.nlm.nih.gov/pubmed/25557638 - Arshanapalli A, Shah M, Veerula V, Somani A.
The role of type I interferons and other cytokines in dermatomyositis.
Cytokine. 2014 Dec 22. pii: S1043-4666(14)00609-7. doi: 10.1016/j.cyto.2014.11.026. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/25541432 - Hornung T, Janzen V, Wenzel J, Heidgen FJ, Wolf D, Bieber T.
Remission of recalcitrant dermatomyositis treated with ruxolitinib.
N Engl J Med. 2014 Dec 25;371(26):2537-8.
http://www.ncbi.nlm.nih.gov/pubmed/25539124 - Palaniappan P, Lionel AP, Kumar S.
Successful treatment of calcinosis cutis in juvenile dermatomyositis with pamidronate.
J Clin Rheumatol. 2014 Dec;20(8):454-5.
http://www.ncbi.nlm.nih.gov/pubmed/25417690 - Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG.
The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.
Curr Rheumatol Rep. 2014 Dec;16(12):467.
http://www.ncbi.nlm.nih.gov/pubmed/25366934
- Palaniappan P, Lionel AP, Kumar S.
Successful treatment of calcinosis cutis in juvenile dermatomyositis with pamidronate.
J Clin Rheumatol. 2014 Dec;20(8):454-5.
http://www.ncbi.nlm.nih.gov/pubmed/?term=24996906 - Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG.
The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.
Curr Rheumatol Rep. 2014 Dec;16(12):467.
http://www.ncbi.nlm.nih.gov/pubmed/?term=25366934 - Bailey EE, Fiorentino DF.
Amyopathic dermatomyositis: definitions, diagnosis, and management.
Curr Rheumatol Rep. 2014 Dec;16(12):465
http://www.ncbi.nlm.nih.gov/pubmed/?term=25366932 - Cappelletti C, Galbardi B, Kapetis D, Vattemi G, Guglielmi V, Tonin P, Salerno F, Morandi L, Tomelleri G, Mantegazza R, Bernasconi P.
Autophagy, inflammation and innate immunity in inflammatory myopathies.
PLoS One. 2014 Nov 3;9(11):e111490.
http://www.ncbi.nlm.nih.gov/pubmed/?term=25365350 - Singh S, Suri D, Aulakh R, Gupta A, Rawat A, Kumar RM.
Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India.
Clin Rheumatol. 2014 Nov;33(11):1675-9.
http://www.ncbi.nlm.nih.gov/pubmed/?term=25053380 - Schwartz T, Sjaastad I, Flatø B, Vistnes M, Christensen G, Sanner H.
In active juvenile dermatomyositis, elevated eotaxin and MCP-1 and cholesterol levels in the upper normal range are associated with cardiac dysfunction.
Rheumatology (Oxford). 2014 Dec;53(12):2214-22.
http://www.ncbi.nlm.nih.gov/pubmed/?term=24996906 - Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR, McHugh NJ; Juvenile Dermatomyositis Research Group.
Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
Rheumatology (Oxford). 2014 Dec;53(12):2204-8.
http://www.ncbi.nlm.nih.gov/pubmed/?term=24987158 - Gerhold K, Becker MO.
Nailfold capillaroscopy in juvenile rheumatic diseases: known measures, patterns and indications.
Clin Exp Rheumatol. 2014 Nov-Dec;32 Suppl 86(6):183-8.
http://www.ncbi.nlm.nih.gov/pubmed/?term=24960119 - Pavlov-Dolijanovic SR, Vujasinovic Stupar NZ, Gavrilov N, Seric S.
Lower extremity lipedema, upper extremity lipodystrophy and severe calcinosis complicating juvenile dermatomyositis.
Rheumatol Int. 2014 Nov;34(11):1615-8.
http://www.ncbi.nlm.nih.gov/pubmed/?term=24789670 - Ernste FC, Reed AM.
Recent advances in juvenile idiopathic inflammatory myopathies
Curr Opin Rheumatol. 2014 Nov;26(6):671-8. doi: 10.1097/BOR.0000000000000103.
http://www.ncbi.nlm.nih.gov/pubmed/25160931
- Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai K, Nakano N, Miyoshi M, Kinjo N, Murata T, Masunaga K, Umebayashi H, Imagawa T, Agematsu K, Sato S, Kuwana M, Yamada M, Takei S, Yokota S, Koike K, Ariga T.
Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
Rheumatology (Oxford). 2014 Oct 6. pii: keu385. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/25288783 - Ernste, Floranne C.; Reed, Ann M.
Recent advances in juvenile idiopathic inflammatory myopathies
Current Opinion in Rheumatology. Nov 2014.
doi: 10.1097/BOR.0000000000000103
http://journals.lww.com/co-rheumatology/Abstract/2014/11000/Recent_advances_in_juvenile_idiopathic.12.aspx
- Sanner H, Sjaastad I, FlatØ B.
Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool.
Rheumatology (2014);53(9):1578-1585.
http://rheumatology.oxfordjournals.org/content/53/9/1578.abstract - Unger L, Kampf S, Lüthke K, Aringer M.
Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population
Rheumatology (2014);53(9):1630-1638
http://rheumatology.oxfordjournals.org/content/53/9/1630.abstract - Castro T, Lederman H, Terreri M, Caldana W, Zanoteli E, Hilário M.
Whole-body magnetic resonance imaging in the assessment of muscular involvement in juvenile dermatomyositis/polymyositis patients.
Scand J Rheumatol. 2014;43(4):329-33.
http://www.ncbi.nlm.nih.gov/pubmed/25087579
- Vercoulen Y, Bellutti Enders F, Meerding J, Plantinga M, Elst EF, Varsani H, van Schieveen C, Bakker MH, Klein M, Scholman RC, Spliet W, Ricotti V, Koenen HJ, de Weger RA, Wedderburn LR, van Royen-Kerkhof A, Prakken BJ.
Increased Presence of FOXP3+ Regulatory T Cells in Inflamed Muscle of Patients with Active Juvenile Dermatomyositis Compared to Peripheral Blood.
PLoS One. 2014 Aug 26;9(8):e105353. doi: 10.1371/journal.pone.0105353. eCollection 2014.
http://www.ncbi.nlm.nih.gov/pubmed/25157414
- Rider LG, Yip AL, Horkayne-Szakaly I, Volochayev R, Shrader JA, Turner ML, Kong HH, Jain MS, Jansen AV, Oddis CV, Fleisher TA, Miller FW.
Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.
Clin Exp Rheumatol. 2014 Jul 28. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/25068290 - Schwartz T1, Sjaastad I2, Flatø B3, Vistnes M3, Christensen G4, Sanner H5.
In active juvenile dermatomyositis, elevated eotaxin and MCP-1 and cholesterol levels in the upper normal range are associated with cardiac dysfunction.
Rheumatology (Oxford). 2014 Jul 4. pii: keu256. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24996906 - Boccaletti V1, Di Nuzzo S, Feliciani C, Fabrizi G, Pagliarello C.
An update on juvenile dermatomyositis.
G Ital Dermatol Venereol. 2014 Jul 18.
http://www.ncbi.nlm.nih.gov/pubmed/25034096 - Singh S1, Suri D, Aulakh R, Gupta A, Rawat A, Kumar RM.
Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India.
Clin Rheumatol. 2014 Jul 23.
http://www.ncbi.nlm.nih.gov/pubmed/25053380 - Yu HH1, Chang HM2, Chiu CJ3, Yang YH1, Lee JH1, Wang LC1, Lin YT1, Chiang BL4.
Detection of anti-p155/140, anti-p140, and antiendothelial cells autoantibodies in patients with juvenile dermatomyositis.
J Microbiol Immunol Infect. 2014 Jul 25.
http://www.ncbi.nlm.nih.gov/pubmed/25070283 - McCann LJ1, Arnold K2, Pilkington CA3, Huber AM4, Ravelli A5, Beard L2, Beresford MW6, Wedderburn LR7.
Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research.
Pediatr Rheumatol Online J. 2014 Jul 21;12:31. doi: 10.1186/1546-0096-12-31. eCollection 2014.
http://www.ncbi.nlm.nih.gov/pubmed/25075205 - Tansley SL1, Betteridge ZE1, Shaddick G1, Gunawardena H1, Arnold K2, Wedderburn LR2, McHugh NJ3; on behalf of the Juvenile Dermatomyositis Research Group.
Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
Rheumatology (Oxford). 2014 Jul 1. pii: keu259. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24987158 - Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, Arnold K, Yasin S, Moraitis E, Wedderburn LR, McHugh NJ.
Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.
Arthritis Res Ther. 2014 Jul 2;16(4):R138. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24989778 - Rheumatology (Oxford). 2014 Jul 1. pii: keu259. [Epub ahead of print]Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
Tansley SL1, Betteridge ZE1, Shaddick G1, Gunawardena H1, Arnold K2, Wedderburn LR2, McHugh NJ3; on behalf of the Juvenile Dermatomyositis Research Group.
http://www.ncbi.nlm.nih.gov/pubmed/24987158 - Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, Arnold K, Yasin S, Moraitis E, Wedderburn LR, McHugh NJ.
Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.
Arthritis Res Ther. 2014 Jul 2;16(4):R138. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24989778
- Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y, Inui N, Yokomura K, Koshimizu N, Toyoshima M, Shirai T, Yasuda K, Hayakawa H, Suda T.
Prognostic factors for myositis-associated interstitial lung disease
PLoS One. 2014 Jun 6;9(6):e98824. doi: 10.1371/journal.pone.0098824. eCollection 2014.
http://www.ncbi.nlm.nih.gov/pubmed/24905449 - Neri R, Barsotti S, Iacopetti V, Tripoli A, dʼAscanio A, Tavoni AG, Mosca M, Bombardieri S.
Clinically amyopathic dermatomyositis: analysis of a monocentric cohort.
J Clin Neuromuscul Dis. 2014 Jun;15(4):157-60. doi: 10.1097/CND.0000000000000038.
http://www.ncbi.nlm.nih.gov/pubmed/24872214
-
Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D.Identification of Clinical Features and Autoantibodies Associated With Calcinosis in Dermatomyositis.JAMA Dermatol. 2014 May 28. doi: 10.1001/jamadermatol.2013.10416. [Epub ahead of print]
- Article in French
Pouessel G1, Thumerelle C2, Nève V3, Santangelo T4, Flammarion S1, Pruvot I5, Tillie-Leblond I6, Deschildre A7.
Lung is also involved in juvenile dermatomyositis.
Rev Med Interne. 2014 May 21.[Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/24856457
- Robinson AB1, Hoeltzel MF, Wahezi DM, Becker ML, Kessler EA, Schmeling H, Carrasco R, Huber AM, Feldman BM, Reed AM; Juvenile Myositis CARRA Subgroup, for the CARRA Registry Investigators.
Clinical characteristics of children with juvenile dermatomyositis: the childhood arthritis and rheumatology research alliance registry.
Arthritis Care Res (Hoboken). 2014 Mar;66(3):404-10. doi: 10.1002/acr.22142.
http://www.ncbi.nlm.nih.gov/pubmed/23983017 - Aggarwal R1, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC; RIM Study Group, Oddis CV.
Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.
Arthritis Rheumatol. 2014 Mar;66(3):740-9. doi: 10.1002/art.38270.
http://www.ncbi.nlm.nih.gov/pubmed/24574235
- McCrea N, Al-Sabbagh A, Ahmed S, Walker D, Rangaraj S.
Onset of juvenile dermatomyositis following varicella infection in a 12-month-old child: a case report.
J Med Case Rep. 2014 Feb 15;8(1):54. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/24529167
- Mamyrova G, Katz JD, Jones RV, Targoff IN, Lachenbruch PA, Jones OY, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.
Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy.
Arthritis Care Res (Hoboken). 2013 Dec;65(12):1969-75. doi: 10.1002/acr.22088.
http://www.ncbi.nlm.nih.gov/pubmed/23925923
- Nistala K, Wedderburn LR.
Update in juvenile myositis.
Curr Opin Rheumatol. 2013 Nov;25(6):742-6.
http://www.ncbi.nlm.nih.gov/pubmed/24061078 - Tansley SL, Betteridge ZE, McHugh NJ.
The diagnostic utility of autoantibodies in adult and juvenile myositis.
Curr Opin Rheumatol. 2013 Nov;25(6):772-7
http://www.ncbi.nlm.nih.gov/pubmed/24047605
- Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, Miller FW, Rider LG; for the Childhood Myositis Heterogeneity Study Group.
Early Illness Features Associated with Mortality in The Juvenile Idiopathic Inflammatory Myopathies.
Arthritis Care Res (Hoboken). 2013 Oct 21.[Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/24151254
- Prestridge A, Morgan G, Ferguson L, Huang CC, Pachman LM.
Pulmonary Function Tests in Idiopathic Inflammatory Myopathy: Association With Clinical Parameters in Children
Arthritis Care Res 2013 Sep; 65(9):1424-31.
http://onlinelibrary.wiley.com/doi/10.1002/acr.22014/abstract -
Robinson AB, Hoeltzel MF, Wahezi DM, Becker ML, Kessler E, Schmeling H, Carrasco R, Huber AM, Feldman BM, Reed AM; Juvenile Myositis CARRA Subgroup; CARRA Registry Investigators.Clinical characteristics of children with juvenile dermatomyositis - the children's arthritis and rheumatology research alliance (CARRA) registry.Arthritis Care Res (Hoboken). 2013 Aug 27. doi: 10.1002/acr.22142. [Epub ahead of print]
-
Martillotti J, Moote D, Zemel L.Improvement of calcinosis using pamidronate in a patient with juvenile dermatomyositis.Pediatr Radiol. 2013 Jul 10. [Epub ahead of print]
- Malattia C, Damasio MB, Madeo A, Pistorio A, Providenti A, Pederzoli S, Viola S, Buoncompagni A, Mattiuz C, Beltramo A, Consolaro A, Ravelli A, Ruperto N, Picco P, Magnano GM, Martini A
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis
Ann Rheum Dis 2013 May 1. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/23636654 - Quiñones R, Morgan GA, Amoruso M, Field R, Huang CC, Pachman LM.
Four-year-olds, healthy or recovering from Juvenile Dermatomyositis, do not achieve a full score on the Childhood Myositis Assessment Scale (CMAS).
Arthritis Care Res (Hoboken) 2013 May 10:NA. doi: 10.1002/acr.22041. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/23666925 - Shah M, Targoff IN, Rice MM, Miller FW, Rider LG; with the Childhood Myositis Heterogeneity Collaborative Study Group.
Ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in Juvenile Myositis.
Arthritis Rheum 2013 May 8. doi: 10.1002/art.37985. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/23658122 - Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, Wulffraat NM, Malattia C, Garay SM, Hofer M, Quartier P, Dolezalova P, Penades IC, Ferriani VP, Ganser G, Kasapcopur O, Melo-Gomes JA, Reed AM, Wierzbowska M, Rider LG, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis
Ann Rheum Dis. 2013 May;72:686-93. doi: 10.1136/annrheumdis-2012-201483.
http://www.ncbi.nlm.nih.gov/pubmed/22736096
- Mathiesen PR, Ørngreen MC, Vissing J, Andersen LB, Herlin T, Nielsen S.
Aerobic fitness after JDM--a long-term follow-up study.
Rheumatology (Oxford). 2013 Feb;52(2):287-95. doi: 10.1093/rheumatology/kes232. Epub 2012 Sep 22.
http://www.ncbi.nlm.nih.gov/pubmed/23001614 -
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE for the Rituximab in Myositis (RIM) Study Group.Rituximab in the treatment of refractory adult and juvenile dermatomiositis and adult polymyositis: A randomized, placebo-phase trial.Arthritis Rheum. 2013 Feb;65(2):314-24. doi: 10.1002/art.37754.
- Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, Miller FW, Rider LG; with the Childhood Myositis Heterogeneity Collaborative Study Group.
The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies.
Medicine (Baltimore). 2013 Jan;92(1):25-41.
http://www.ncbi.nlm.nih.gov/pubmed/23263716
- Pouessel G, Deschildre A, Le Bourgeois M, Cuisset JM, Catteau B, Karila C, Nève V, Thumerelle C, Quartier P, Tillie-Leblond I.
The lung is involved in juvenile dermatomyositis.
Pediatr Pulmonol. 2012 Dec 31. doi: 10.1002/ppul.22742. [Epub ahead of print]http://onlinelibrary.wiley.com/doi/10.1002/ppul.22742/pdf - Reed AM, Peterson E, Bilgic H. Ytterberg SR, Amin S, Hein MS, Crowson CS, Ernste F, Gillespie EB.
Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course.
Arthritis Rheum 2012 Dec; 64(12):4078–86. DOI: 10.1002/art.34659.
http://onlinelibrary.wiley.com/doi/10.1002/art.34659/abstract
- Patwardhan A, Rennebohm RM, Dvorchik I, Spencer CH.
Is juvenile dermatomiositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of single center experience.
Pediatr Rheumatol Online J. 2012 Sep 20;10(1):34. [Epub ahead of print].
http://www.ncbi.nlm.nih.gov/pubmed/22995763
- Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, Curran M, Feldman BM, Gewanter H, Griffin T, Haines K, Hoeltzel MF, Isgro J, Kahn P, Lang B, Lawler P, Shaham B, Schmeling H, Scuccimarri R, Shishov M, Stringer E, Wohrley J, Ilowite NT, Wallace C; Juvenile Dermatomyositis Subcommittee of the Childhood Arthritis and Rheumatology Research Alliance.
Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference.
Arthritis Care Res (Hoboken). 2012 Apr;64(4):546-53. doi: 10.1002/acr.20695.
http://www.ncbi.nlm.nih.gov/pubmed/22076847
